You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameQuetiapine
Accession NumberDB01224  (APRD00675)
TypeSmall Molecule
GroupsApproved
DescriptionQuetiapine is indicated for the treatment of schizophrenia as well as for the treatment of acute manic episodes associated with bipolar I disorder. The antipsychotic effect of quetiapine is thought by some to be mediated through antagonist activity at dopamine and serotonin receptors. Specifically the D1 and D2 dopamine, the alpha 1 adrenoreceptor and alpha 2 adrenoreceptor, and 5-HT1A and 5-HT2 serotonin receptor subtypes are antagonized. Quetiapine also has an antagonistic effect on the histamine H1 receptor.
Structure
Thumb
Synonyms
2-[2-(4-Dibenzo[b,F][1,4]thiazepin-11-yl-1-piperazinyl)ethoxy]ethanol
Quetiapina
Quetiapine
Quetiapine fumarate
Quetiapine hemifumarate
Quetiapinum
External Identifiers Not Available
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Abbott-quetiapineTablet, multilayer, extended release25 mgOralBgp Pharma Ulc2014-06-092015-12-31Canada
Abbott-quetiapineTablet, multilayer, extended release100 mgOralBgp Pharma Ulc2014-06-092015-12-31Canada
Abbott-quetiapineTablet, multilayer, extended release200 mgOralBgp Pharma Ulc2014-06-132015-12-31Canada
Abbott-quetiapineTablet, multilayer, extended release300 mgOralBgp Pharma Ulc2014-06-092015-12-31Canada
Accel-quetiapineTablet25 mgOralAccel Pharma Inc2015-03-26Not applicableCanada
Accel-quetiapineTablet300 mgOralAccel Pharma Inc2015-03-26Not applicableCanada
Accel-quetiapineTablet100 mgOralAccel Pharma Inc2015-03-26Not applicableCanada
Accel-quetiapineTablet150 mgOralAccel Pharma Inc2015-03-03Not applicableCanada
Accel-quetiapineTablet200 mgOralAccel Pharma Inc2015-03-26Not applicableCanada
Ach-quetiapine Fumarate XRTablet, extended release400 mgOralAccord Healthcare IncNot applicableNot applicableCanada
Ach-quetiapine Fumarate XRTablet, extended release300 mgOralAccord Healthcare IncNot applicableNot applicableCanada
Ach-quetiapine Fumarate XRTablet, extended release50 mgOralAccord Healthcare IncNot applicableNot applicableCanada
Ach-quetiapine Fumarate XRTablet, extended release150 mgOralAccord Healthcare IncNot applicableNot applicableCanada
Ach-quetiapine Fumarate XRTablet, extended release200 mgOralAccord Healthcare IncNot applicableNot applicableCanada
Act QuetiapineTablet300 mgOralActavis Pharma Company2008-09-04Not applicableCanada
Act QuetiapineTablet25 mgOralActavis Pharma Company2008-09-04Not applicableCanada
Act QuetiapineTablet100 mgOralActavis Pharma Company2008-09-04Not applicableCanada
Act QuetiapineTablet200 mgOralActavis Pharma Company2008-09-04Not applicableCanada
Act QuetiapineTablet150 mgOralActavis Pharma CompanyNot applicableNot applicableCanada
Auro-quetiapineTablet200 mgOralAuro Pharma Inc2012-10-18Not applicableCanada
Auro-quetiapineTablet300 mgOralAuro Pharma Inc2012-10-18Not applicableCanada
Auro-quetiapineTablet25 mgOralAuro Pharma Inc2012-10-18Not applicableCanada
Auro-quetiapineTablet150 mgOralAuro Pharma IncNot applicableNot applicableCanada
Auro-quetiapineTablet100 mgOralAuro Pharma Inc2012-10-18Not applicableCanada
Ava-quetiapineTablet200 mgOralAvanstra Inc2011-11-282014-08-21Canada
Ava-quetiapineTablet25 mgOralAvanstra Inc2011-11-282014-08-21Canada
Ava-quetiapineTablet100 mgOralAvanstra Inc2011-11-282014-08-21Canada
Bio-quetiapineTablet100 mgOralBiomed Pharma2016-09-07Not applicableCanada
Bio-quetiapineTablet200 mgOralBiomed Pharma2016-09-07Not applicableCanada
Bio-quetiapineTablet150 mgOralBiomed PharmaNot applicableNot applicableCanada
Bio-quetiapineTablet300 mgOralBiomed Pharma2016-09-07Not applicableCanada
Bio-quetiapineTablet25 mgOralBiomed Pharma2016-09-07Not applicableCanada
Dom-quetiapineTablet300 mgOralDominion Pharmacal2010-07-01Not applicableCanada
Dom-quetiapineTablet25 mgOralDominion Pharmacal2010-05-01Not applicableCanada
Dom-quetiapineTablet150 mgOralDominion PharmacalNot applicableNot applicableCanada
Dom-quetiapineTablet100 mgOralDominion Pharmacal2010-06-01Not applicableCanada
Dom-quetiapineTablet200 mgOralDominion Pharmacal2010-05-01Not applicableCanada
Ipg-quetiapineTablet, multilayer, extended release200 mgOralInternational Pharmaceutical Generics LtdNot applicableNot applicableCanada
Ipg-quetiapineTablet, multilayer, extended release300 mgOralInternational Pharmaceutical Generics LtdNot applicableNot applicableCanada
Ipg-quetiapineTablet, multilayer, extended release25 mgOralInternational Pharmaceutical Generics LtdNot applicableNot applicableCanada
Ipg-quetiapineTablet, multilayer, extended release100 mgOralInternational Pharmaceutical Generics LtdNot applicableNot applicableCanada
Jamp-quetiapineTablet300 mgOralJamp Pharma Corporation2010-06-18Not applicableCanada
Jamp-quetiapineTablet150 mgOralJamp Pharma CorporationNot applicableNot applicableCanada
Jamp-quetiapineTablet25 mgOralJamp Pharma Corporation2010-04-02Not applicableCanada
Jamp-quetiapineTablet100 mgOralJamp Pharma Corporation2010-04-02Not applicableCanada
Jamp-quetiapineTablet200 mgOralJamp Pharma Corporation2010-04-02Not applicableCanada
Mar-quetiapineTablet, multilayer, extended release100 mgOralMarcan Pharmaceuticals Inc2014-01-16Not applicableCanada
Mar-quetiapineTablet, multilayer, extended release200 mgOralMarcan Pharmaceuticals Inc2014-01-16Not applicableCanada
Mar-quetiapineTablet, multilayer, extended release300 mgOralMarcan Pharmaceuticals Inc2014-01-16Not applicableCanada
Mar-quetiapineTablet, multilayer, extended release25 mgOralMarcan Pharmaceuticals Inc2014-01-16Not applicableCanada
Mint-quetiapineTablet100 mgOralMint Pharmaceuticals Inc2015-03-19Not applicableCanada
Mint-quetiapineTablet200 mgOralMint Pharmaceuticals Inc2015-03-19Not applicableCanada
Mint-quetiapineTablet300 mgOralMint Pharmaceuticals Inc2015-03-19Not applicableCanada
Mint-quetiapineTablet25 mgOralMint Pharmaceuticals Inc2015-03-19Not applicableCanada
Mint-quetiapineTablet150 mgOralMint Pharmaceuticals IncNot applicableNot applicableCanada
Mylan-quetiapineTablet200 mgOralMylan Pharmaceuticals Ulc2008-09-04Not applicableCanada
Mylan-quetiapineTablet300 mgOralMylan Pharmaceuticals Ulc2008-09-04Not applicableCanada
Mylan-quetiapineTablet25 mgOralMylan Pharmaceuticals Ulc2008-09-04Not applicableCanada
Mylan-quetiapineTablet100 mgOralMylan Pharmaceuticals Ulc2008-09-04Not applicableCanada
Nat-quetiapineTablet25 mgOralNatco Pharma (Canada) Inc2015-07-22Not applicableCanada
Nat-quetiapineTablet300 mgOralNatco Pharma (Canada) Inc2015-07-22Not applicableCanada
Nat-quetiapineTablet100 mgOralNatco Pharma (Canada) Inc2015-07-22Not applicableCanada
Nat-quetiapineTablet150 mgOralNatco Pharma (Canada) Inc2015-07-22Not applicableCanada
Nat-quetiapineTablet200 mgOralNatco Pharma (Canada) Inc2015-07-22Not applicableCanada
Nu-quetiapineTablet25 mgOralNu Pharm IncNot applicableNot applicableCanada
Nu-quetiapineTablet100 mgOralNu Pharm IncNot applicableNot applicableCanada
Nu-quetiapineTablet200 mgOralNu Pharm IncNot applicableNot applicableCanada
Nu-quetiapineTablet300 mgOralNu Pharm IncNot applicableNot applicableCanada
PHL-quetiapineTablet300 mgOralPharmel Inc2010-02-182016-10-25Canada
PHL-quetiapineTablet25 mgOralPharmel Inc2010-02-182016-10-25Canada
PHL-quetiapineTablet100 mgOralPharmel Inc2010-02-182016-10-25Canada
PHL-quetiapineTablet200 mgOralPharmel Inc2010-02-182016-10-25Canada
PMS-quetiapineTablet300 mgOralPharmascience Inc2008-09-04Not applicableCanada
PMS-quetiapineTablet25 mgOralPharmascience Inc2008-09-04Not applicableCanada
PMS-quetiapineTablet50 mgOralPharmascience Inc2011-01-21Not applicableCanada
PMS-quetiapineTablet100 mgOralPharmascience Inc2008-09-04Not applicableCanada
PMS-quetiapineTablet150 mgOralPharmascience IncNot applicableNot applicableCanada
PMS-quetiapineTablet200 mgOralPharmascience Inc2008-09-04Not applicableCanada
Priva-quetiapineTablet100 mgOralPharmapar Inc2016-09-07Not applicableCanada
Priva-quetiapineTablet200 mgOralPharmapar Inc2016-09-07Not applicableCanada
Priva-quetiapineTablet150 mgOralPharmapar IncNot applicableNot applicableCanada
Priva-quetiapineTablet300 mgOralPharmapar Inc2016-09-07Not applicableCanada
Priva-quetiapineTablet25 mgOralPharmapar Inc2016-09-07Not applicableCanada
Pro-quetiapineTablet100 mgOralPro Doc Limitee2008-10-23Not applicableCanada
Pro-quetiapineTablet200 mgOralPro Doc Limitee2008-10-23Not applicableCanada
Pro-quetiapineTablet300 mgOralPro Doc Limitee2008-10-23Not applicableCanada
Pro-quetiapineTablet25 mgOralPro Doc Limitee2008-10-23Not applicableCanada
QuetiapineTablet200 mgOralSivem Pharmaceuticals Ulc2009-02-26Not applicableCanada
QuetiapineTablet300 mgOralCobalt Pharmaceuticals CompanyNot applicableNot applicableCanada
QuetiapineTablet25 mgOralCobalt Pharmaceuticals CompanyNot applicableNot applicableCanada
QuetiapineTablet25 mgOralSanis Health Inc2010-07-26Not applicableCanada
QuetiapineTablet300 mgOralSivem Pharmaceuticals Ulc2009-02-26Not applicableCanada
QuetiapineTablet100 mgOralCobalt Pharmaceuticals CompanyNot applicableNot applicableCanada
QuetiapineTablet100 mgOralSanis Health Inc2010-07-26Not applicableCanada
QuetiapineTablet25 mgOralSivem Pharmaceuticals Ulc2009-02-26Not applicableCanada
QuetiapineTablet150 mgOralCobalt Pharmaceuticals CompanyNot applicableNot applicableCanada
QuetiapineTablet200 mgOralSanis Health Inc2010-07-26Not applicableCanada
QuetiapineTablet100 mgOralSivem Pharmaceuticals Ulc2009-02-26Not applicableCanada
QuetiapineTablet200 mgOralCobalt Pharmaceuticals CompanyNot applicableNot applicableCanada
QuetiapineTablet300 mgOralSanis Health Inc2010-07-26Not applicableCanada
Quetiapine Fumarate Extended ReleaseTablet, extended release200 mg/1OralPar Pharmaceutical Inc.2016-11-01Not applicableUs
Quetiapine Fumarate Extended ReleaseTablet, extended release300 mg/1OralPar Pharmaceutical Inc.2016-11-01Not applicableUs
Quetiapine Fumarate Extended ReleaseTablet, extended release50 mg/1OralPar Pharmaceutical Inc.2016-11-01Not applicableUs
Quetiapine Fumarate Extended ReleaseTablet, extended release150 mg/1OralPar Pharmaceutical Inc.2016-11-01Not applicableUs
Quetiapine TabletsTablet25 mgOralAccord Healthcare Inc2012-06-20Not applicableCanada
Quetiapine TabletsTablet300 mgOralAccord Healthcare Inc2012-06-20Not applicableCanada
Quetiapine TabletsTablet100 mgOralAccord Healthcare Inc2012-06-20Not applicableCanada
Quetiapine TabletsTablet150 mgOralAccord Healthcare Inc2012-06-20Not applicableCanada
Quetiapine TabletsTablet200 mgOralAccord Healthcare Inc2012-06-20Not applicableCanada
Quetiapine XRTablet, extended release200 mgOralSivem Pharmaceuticals Ulc2014-01-16Not applicableCanada
Quetiapine XRTablet, extended release150 mgOralPro Doc Limitee2014-01-09Not applicableCanada
Quetiapine XRTablet, extended release50 mgOralPro Doc Limitee2014-01-09Not applicableCanada
Quetiapine XRTablet, extended release300 mgOralSivem Pharmaceuticals Ulc2014-01-16Not applicableCanada
Quetiapine XRTablet, extended release50 mgOralSivem Pharmaceuticals Ulc2014-01-01Not applicableCanada
Quetiapine XRTablet, extended release200 mgOralPro Doc Limitee2014-01-09Not applicableCanada
Quetiapine XRTablet, extended release300 mgOralPro Doc Limitee2014-01-09Not applicableCanada
Quetiapine XRTablet, extended release400 mgOralSivem Pharmaceuticals Ulc2014-01-16Not applicableCanada
Quetiapine XRTablet, extended release400 mgOralPro Doc Limitee2014-01-09Not applicableCanada
Quetiapine XRTablet, extended release150 mgOralSivem Pharmaceuticals Ulc2014-01-16Not applicableCanada
Ran-quetiapineTablet100 mgOralRanbaxy Pharmaceuticals Canada Inc.2013-01-17Not applicableCanada
Ran-quetiapineTablet200 mgOralRanbaxy Pharmaceuticals Canada Inc.2013-01-17Not applicableCanada
Ran-quetiapineTablet300 mgOralRanbaxy Pharmaceuticals Canada Inc.2013-01-17Not applicableCanada
Ran-quetiapineTablet25 mgOralRanbaxy Pharmaceuticals Canada Inc.2013-01-17Not applicableCanada
Ratio-quetiapineTablet200 mgOralRatiopharm Inc Division Of Teva Canada Limited2008-08-272014-09-19Canada
Ratio-quetiapineTablet300 mgOralRatiopharm Inc Division Of Teva Canada Limited2008-08-272014-09-19Canada
Ratio-quetiapineTablet25 mgOralRatiopharm Inc Division Of Teva Canada Limited2008-08-222014-09-19Canada
Ratio-quetiapineTablet100 mgOralRatiopharm Inc Division Of Teva Canada Limited2008-08-272014-09-19Canada
Riva-quetiapineTablet200 mgOralLaboratoire Riva Inc2008-09-24Not applicableCanada
Riva-quetiapineTablet300 mgOralLaboratoire Riva Inc2008-09-24Not applicableCanada
Riva-quetiapineTablet25 mgOralLaboratoire Riva Inc2008-09-24Not applicableCanada
Riva-quetiapineTablet150 mgOralLaboratoire Riva IncNot applicableNot applicableCanada
Riva-quetiapineTablet100 mgOralLaboratoire Riva Inc2008-09-24Not applicableCanada
Sandoz QuetiapineTablet200 mgOralSandoz Canada Incorporated2008-09-04Not applicableCanada
Sandoz QuetiapineTablet300 mgOralSandoz Canada Incorporated2008-09-04Not applicableCanada
Sandoz QuetiapineTablet25 mgOralSandoz Canada Incorporated2008-09-04Not applicableCanada
Sandoz QuetiapineTablet100 mgOralSandoz Canada Incorporated2008-09-04Not applicableCanada
Sandoz Quetiapine XRTablet, extended release200 mgOralSandoz Canada IncorporatedNot applicableNot applicableCanada
Sandoz Quetiapine XRTablet, extended release50 mgOralSandoz Canada IncorporatedNot applicableNot applicableCanada
Sandoz Quetiapine XRTablet, extended release300 mgOralSandoz Canada IncorporatedNot applicableNot applicableCanada
Sandoz Quetiapine XRTablet, extended release400 mgOralSandoz Canada IncorporatedNot applicableNot applicableCanada
Sandoz Quetiapine XRTablet, extended release150 mgOralSandoz Canada IncorporatedNot applicableNot applicableCanada
Sandoz Quetiapine XrtTablet, extended release150 mgOralSandoz Canada Incorporated2013-06-14Not applicableCanada
Sandoz Quetiapine XrtTablet, extended release200 mgOralSandoz Canada Incorporated2013-06-14Not applicableCanada
Sandoz Quetiapine XrtTablet, extended release300 mgOralSandoz Canada Incorporated2013-06-14Not applicableCanada
Sandoz Quetiapine XrtTablet, extended release400 mgOralSandoz Canada Incorporated2013-06-14Not applicableCanada
Sandoz Quetiapine XrtTablet, extended release50 mgOralSandoz Canada Incorporated2013-06-14Not applicableCanada
SeroquelTablet, film coated25 mg/1OralRebel Distributors Corp2010-06-01Not applicableUs
SeroquelTablet, film coated200 mg/1OralLake Erie Medical DBA Quality Care Products LLC2010-07-08Not applicableUs
SeroquelTablet, film coated100 mg/1OralAstra Zeneca Pharmaceuticals Lp1997-10-01Not applicableUs
SeroquelTablet, film coated200 mg/1Oralbryant ranch prepack1997-10-01Not applicableUs
SeroquelTablet, film coated200 mg/1OralCardinal Health2010-06-01Not applicableUs
SeroquelTablet, film coated25 mg/1OralContract Pharmacy Services Pa2010-06-01Not applicableUs
SeroquelTablet, film coated25 mg/1OralREMEDYREPACK INC.2013-05-092016-04-05Us
SeroquelTablet, film coated100 mg/1OralREMEDYREPACK INC.2013-04-242016-03-04Us
SeroquelTablet, film coated50 mg/1OralPhysicians Total Care, Inc.2006-04-28Not applicableUs
SeroquelTablet, film coated50 mg/1OralAstra Zeneca Pharmaceuticals Lp2006-02-13Not applicableUs
SeroquelTablet, film coated50 mg/1OralREMEDYREPACK INC.2013-05-092016-10-13Us
SeroquelTablet, film coated25 mg/1OralPd Rx Pharmaceuticals, Inc.2011-07-19Not applicableUs
SeroquelTablet, film coated300 mg/1OralContract Pharmacy Services Pa2010-06-01Not applicableUs
SeroquelTablet, film coated300 mg/1Oralbryant ranch prepack2000-11-13Not applicableUs
SeroquelTablet, film coated50 mg/1OralRebel Distributors Corp2010-06-01Not applicableUs
SeroquelTablet, film coated100 mg/1OralPhysicians Total Care, Inc.2006-04-28Not applicableUs
SeroquelTablet, film coated200 mg/1OralAstra Zeneca Pharmaceuticals Lp1997-10-01Not applicableUs
SeroquelTablet, film coated300 mg/1OralCardinal Health2010-06-01Not applicableUs
SeroquelTablet, film coated50 mg/1OralContract Pharmacy Services Pa2010-06-01Not applicableUs
SeroquelTablet, film coated50 mg/1OralLake Erie Medical & Surgical Supply DBA Quality Care Products LLC2012-04-16Not applicableUs
SeroquelTablet, film coated200 mg/1OralREMEDYREPACK INC.2013-04-102016-04-05Us
SeroquelTablet, film coated400 mg/1OralAstra Zeneca Pharmaceuticals Lp2006-02-13Not applicableUs
SeroquelTablet, film coated100 mg/1OralSTAT Rx USA LLC2011-05-26Not applicableUs
SeroquelTablet, film coated100 mg/1OralLake Erie Medical & Surgical Supply DBA Quality Care Products LLC2012-04-16Not applicableUs
SeroquelTablet, film coated100 mg/1Oralbryant ranch prepack1997-10-01Not applicableUs
SeroquelTablet, film coated400 mg/1OralContract Pharmacy Services Pa2010-06-01Not applicableUs
SeroquelTablet, film coated25 mg/1OralPhysicians Total Care, Inc.2003-11-19Not applicableUs
SeroquelTablet, film coated300 mg/1OralAstra Zeneca Pharmaceuticals Lp2000-11-13Not applicableUs
SeroquelTablet, film coated50 mg/1Oralbryant ranch prepack2006-02-13Not applicableUs
SeroquelTablet, film coated100 mg/1OralRebel Distributors Corp2010-06-01Not applicableUs
SeroquelTablet, film coated300 mg/1OralLake Erie Medical DBA Quality Care Products LLC2010-07-07Not applicableUs
SeroquelTablet, film coated100 mg/1OralPd Rx Pharmaceuticals, Inc.2011-11-18Not applicableUs
SeroquelTablet, film coated100 mg/1OralContract Pharmacy Services Pa2010-06-01Not applicableUs
SeroquelTablet, film coated300 mg/1OralREMEDYREPACK INC.2013-04-102016-03-11Us
SeroquelTablet, film coated25 mg/1OralCardinal Health2010-06-01Not applicableUs
SeroquelTablet, film coated400 mg/1OralSTAT Rx USA LLC2011-05-26Not applicableUs
SeroquelTablet, film coated25 mg/1OralLake Erie Medical & Surgical Supply DBA Quality Care Products LLC2012-04-16Not applicableUs
SeroquelTablet, film coated25 mg/1Oralbryant ranch prepack2003-06-30Not applicableUs
SeroquelTablet, film coated200 mg/1OralRebel Distributors Corp2010-06-01Not applicableUs
SeroquelTablet, film coated300 mg/1OralPhysicians Total Care, Inc.2011-11-18Not applicableUs
SeroquelTablet, film coated25 mg/1OralAstra Zeneca Pharmaceuticals Lp1997-10-01Not applicableUs
SeroquelTablet, extended release150 mg/1OralREMEDYREPACK INC.2011-03-232016-10-13Us
SeroquelTablet, film coated200 mg/1OralPd Rx Pharmaceuticals, Inc.1997-10-01Not applicableUs
SeroquelTablet, film coated200 mg/1OralContract Pharmacy Services Pa2010-06-01Not applicableUs
SeroquelTablet, film coated400 mg/1OralREMEDYREPACK INC.2013-04-102016-03-11Us
SeroquelTablet, film coated100 mg/1OralCardinal Health2010-06-01Not applicableUs
SeroquelTablet, film coated50 mg/1OralREMEDYREPACK INC.2008-08-19Not applicableUs
Seroquel 150 mgTablet150 mgOralAstrazeneca Canada Inc2001-01-102006-03-03Canada
Seroquel 300 mgTablet300 mgOralAstrazeneca Canada Inc2001-08-21Not applicableCanada
Seroquel Tab 100mgTablet100 mgOralAstrazeneca Canada Inc1997-12-10Not applicableCanada
Seroquel Tab 200mgTablet200 mgOralAstrazeneca Canada Inc1997-12-10Not applicableCanada
Seroquel Tab 25mgTablet25 mgOralAstrazeneca Canada Inc1997-12-10Not applicableCanada
Seroquel XRTablet, extended release300 mgOralAstrazeneca Canada Inc2007-09-27Not applicableCanada
Seroquel XRTablet, extended release50 mg/1OralAstra Zeneca Pharmaceuticals Lp2009-02-01Not applicableUs
Seroquel XRTablet, extended release50 mg/1OralREMEDYREPACK INC.2016-10-11Not applicableUs
Seroquel XRTablet, extended release150 mg/1OralTYA Pharmaceuticals2009-02-01Not applicableUs
Seroquel XRTablet, extended release400 mg/1OralAstra Zeneca Pharmaceuticals Lp2007-07-16Not applicableUs
Seroquel XRTablet, extended release400 mgOralAstrazeneca Canada Inc2007-09-27Not applicableCanada
Seroquel XRTablet, extended release150 mg/1OralAstra Zeneca Pharmaceuticals Lp2009-02-01Not applicableUs
Seroquel XRTablet, extended release50 mg/1OralPhysicians Total Care, Inc.2011-11-17Not applicableUs
Seroquel XRTablet, extended release200 mg/1OralTYA Pharmaceuticals2007-07-16Not applicableUs
Seroquel XRTablet, extended release50 mgOralAstrazeneca Canada Inc2007-09-27Not applicableCanada
Seroquel XRTablet, extended release200 mg/1OralAstra Zeneca Pharmaceuticals Lp2007-07-16Not applicableUs
Seroquel XRKitAstra Zeneca Pharmaceuticals Lp2014-10-02Not applicableUs
Seroquel XRTablet, extended release300 mg/1OralTYA Pharmaceuticals2007-07-16Not applicableUs
Seroquel XRTablet, extended release200 mgOralAstrazeneca Canada Inc2007-09-27Not applicableCanada
Seroquel XRTablet, extended release150 mgOralAstrazeneca Canada Inc2009-04-14Not applicableCanada
Seroquel XRTablet, extended release50 mg/1OralTYA Pharmaceuticals2009-02-01Not applicableUs
Seroquel XRTablet, extended release300 mg/1OralAstra Zeneca Pharmaceuticals Lp2007-07-16Not applicableUs
Seroquel XRTablet, extended release400 mg/1OralTYA Pharmaceuticals2007-07-16Not applicableUs
Teva-quetiapineTablet100 mgOralTeva Canada Limited2008-09-04Not applicableCanada
Teva-quetiapineTablet150 mgOralTeva Canada Limited2008-09-04Not applicableCanada
Teva-quetiapineTablet200 mgOralTeva Canada Limited2008-09-04Not applicableCanada
Teva-quetiapineTablet25 mgOralTeva Canada Limited2008-09-04Not applicableCanada
Teva-quetiapineTablet300 mgOralTeva Canada Limited2008-09-04Not applicableCanada
Teva-quetiapine XRTablet, extended release200 mgOralTeva Canada Limited2013-03-08Not applicableCanada
Teva-quetiapine XRTablet, extended release300 mgOralTeva Canada Limited2013-03-08Not applicableCanada
Teva-quetiapine XRTablet, extended release50 mgOralTeva Canada Limited2013-03-08Not applicableCanada
Teva-quetiapine XRTablet, extended release400 mgOralTeva Canada Limited2013-03-08Not applicableCanada
Teva-quetiapine XRTablet, extended release150 mgOralTeva Canada Limited2013-03-08Not applicableCanada
Torrent-quetiapine FumarateTablet, multilayer, extended release300 mgOralTorrent Pharmaceuticals LimitedNot applicableNot applicableCanada
Torrent-quetiapine FumarateTablet, multilayer, extended release25 mgOralTorrent Pharmaceuticals LimitedNot applicableNot applicableCanada
Torrent-quetiapine FumarateTablet, multilayer, extended release100 mgOralTorrent Pharmaceuticals LimitedNot applicableNot applicableCanada
Torrent-quetiapine FumarateTablet, multilayer, extended release200 mgOralTorrent Pharmaceuticals LimitedNot applicableNot applicableCanada
Van-quetiapineTablet100 mgOralVanc Pharmaceuticals Inc2015-06-22Not applicableCanada
Van-quetiapineTablet200 mgOralVanc Pharmaceuticals Inc2015-06-22Not applicableCanada
Van-quetiapineTablet300 mgOralVanc Pharmaceuticals Inc2015-06-22Not applicableCanada
Van-quetiapineTablet25 mgOralVanc Pharmaceuticals Inc2015-06-22Not applicableCanada
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Apo-quetiapineTablet300 mgOralApotex Inc2008-09-04Not applicableCanada
Apo-quetiapineTablet25 mgOralApotex Inc2008-09-04Not applicableCanada
Apo-quetiapineTablet100 mgOralApotex Inc2008-09-04Not applicableCanada
Apo-quetiapineTablet200 mgOralApotex Inc2008-09-04Not applicableCanada
Apo-quetiapine XRTablet, extended release150 mgOralApotex IncNot applicableNot applicableCanada
Apo-quetiapine XRTablet, extended release200 mgOralApotex IncNot applicableNot applicableCanada
Apo-quetiapine XRTablet, extended release300 mgOralApotex IncNot applicableNot applicableCanada
Apo-quetiapine XRTablet, extended release50 mgOralApotex IncNot applicableNot applicableCanada
Apo-quetiapine XRTablet, extended release400 mgOralApotex IncNot applicableNot applicableCanada
QuetiapineTablet, film coated200 mg/1OralAccord Healthcare Inc.2012-03-26Not applicableUs
QuetiapineTablet, film coated300 mg/1OralREMEDYREPACK INC.2016-11-03Not applicableUs
QuetiapineTablet, film coated200 mg/1OralA S Medication Solutions2012-03-28Not applicableUs
QuetiapineTablet, film coated200 mg/1OralTeva Pharmaceuticals Usa, Inc.2012-03-27Not applicableUs
QuetiapineTablet, film coated200 mg/1OralREMEDYREPACK INC.2016-08-18Not applicableUs
QuetiapineTablet, film coated50 mg/1OralREMEDYREPACK INC.2016-10-17Not applicableUs
QuetiapineTablet, film coated25 mg/1OralAccord Healthcare Inc.2012-03-26Not applicableUs
QuetiapineTablet, film coated50 mg/1OralREMEDYREPACK INC.2014-04-14Not applicableUs
QuetiapineTablet, film coated50 mg/1OralREMEDYREPACK INC.2016-10-28Not applicableUs
QuetiapineTablet, film coated300 mg/1OralAccord Healthcare Inc.2012-03-26Not applicableUs
QuetiapineTablet, film coated300 mg/1OralTeva Pharmaceuticals Usa, Inc.2012-03-27Not applicableUs
QuetiapineTablet, film coated100 mg/1OralA S Medication Solutions2012-03-27Not applicableUs
QuetiapineTablet, film coated400 mg/1OralREMEDYREPACK INC.2016-08-182016-10-19Us
QuetiapineTablet, film coated25 mg/1OralA S Medication Solutions2012-03-28Not applicableUs
QuetiapineTablet, film coated50 mg/1OralAccord Healthcare Inc.2012-03-26Not applicableUs
QuetiapineTablet, film coated100 mg/1OralREMEDYREPACK INC.2016-07-26Not applicableUs
QuetiapineTablet, film coated400 mg/1OralAccord Healthcare Inc.2012-03-26Not applicableUs
QuetiapineTablet, film coated400 mg/1OralTeva Pharmaceuticals Usa, Inc.2012-03-27Not applicableUs
QuetiapineTablet, film coated25 mg/1OralA S Medication Solutions2014-03-12Not applicableUs
QuetiapineTablet, film coated400 mg/1OralREMEDYREPACK INC.2016-08-22Not applicableUs
QuetiapineTablet, film coated25 mg/1OralTeva Pharmaceuticals Usa, Inc.2014-03-12Not applicableUs
QuetiapineTablet, film coated100 mg/1OralREMEDYREPACK INC.2016-11-03Not applicableUs
QuetiapineTablet, film coated100 mg/1OralAccord Healthcare Inc.2012-03-26Not applicableUs
QuetiapineTablet, film coated50 mg/1OralTeva Pharmaceuticals Usa, Inc.2012-03-27Not applicableUs
QuetiapineTablet, film coated400 mg/1OralA S Medication Solutions2012-03-28Not applicableUs
QuetiapineTablet, film coated50 mg/1OralREMEDYREPACK INC.2016-09-20Not applicableUs
QuetiapineTablet, film coated100 mg/1OralTeva Pharmaceuticals Usa, Inc.2012-03-27Not applicableUs
Quetiapine FumarateTablet25 mg/1OralWest Ward Pharmaceuticals Corp2012-03-27Not applicableUs
Quetiapine FumarateTablet, film coated50 mg/1OralREMEDYREPACK INC.2013-02-072016-10-13Us
Quetiapine FumarateTablet, film coated200 mg/1OralCardinal Health2012-04-02Not applicableUs
Quetiapine FumarateTablet400 mg/1OralCardinal Health2013-03-01Not applicableUs
Quetiapine FumarateTablet, film coated300 mg/1OralREMEDYREPACK INC.2015-06-29Not applicableUs
Quetiapine FumarateTablet, film coated200 mg/1Oralbryant ranch prepack2012-03-26Not applicableUs
Quetiapine FumarateTablet, film coated25 mg/1OralAmerican Health Packaging2012-04-02Not applicableUs
Quetiapine FumarateTablet100 mg/1OralREMEDYREPACK INC.2014-10-13Not applicableUs
Quetiapine FumarateTablet100 mg/1OralBlue Point Laboratories2013-02-28Not applicableUs
Quetiapine FumarateTablet, film coated50 mg/1OralUnichem Pharmaceuticals (USA), Inc.2016-07-01Not applicableUs
Quetiapine FumarateTablet, film coated300 mg/1OralNorth Star Rx Llc2012-03-272016-10-13Us
Quetiapine FumarateTablet, film coated25 mg/1OralAphena Pharma Solutions Tennessee, Llc2015-07-21Not applicableUs
Quetiapine FumarateTablet, film coated400 mg/1OralBreckenridge Pharmaceutical, Inc2012-03-26Not applicableUs
Quetiapine FumarateTablet, film coated50 mg/1OralMajor Pharmaceuticals2012-04-02Not applicableUs
Quetiapine FumarateTablet200 mg/1OralREMEDYREPACK INC.2016-05-17Not applicableUs
Quetiapine FumarateTablet, film coated50 mg/1OralDr.Reddy's Laboratories Limited2012-03-27Not applicableUs
Quetiapine FumarateTablet, film coated400 mg/1OralGolden State Medical Supply, Inc.2015-07-21Not applicableUs
Quetiapine FumarateTablet, film coated100 mg/1OralAphena Pharma Solutions Tennessee, Llc2012-03-27Not applicableUs
Quetiapine FumarateTablet, film coated200 mg/1OralAvera Mc Kennan Hospital2015-07-29Not applicableUs
Quetiapine FumarateTablet, film coated25 mg/1OralAv Kare, Inc.2014-01-17Not applicableUs
Quetiapine FumarateTablet25 mg/1OralLUPIN LIMITED2012-03-27Not applicableUs
Quetiapine FumarateTablet, film coated25 mg/1OralAlembic Pharmaceuticals Limited2012-03-26Not applicableUs
Quetiapine FumarateTablet, film coated400 mg/1OralSun Pharma Global FZE2012-03-28Not applicableUs
Quetiapine FumarateTablet, film coated100 mg/1OralCardinal Health2012-04-02Not applicableUs
Quetiapine FumarateTablet, film coated25 mg/1OralCitron Pharma LLC2012-03-27Not applicableUs
Quetiapine FumarateTablet, film coated50 mg/1OralGolden State Medical Supply, Inc.2012-03-27Not applicableUs
Quetiapine FumarateTablet400 mg/1OralSandoz Inc2013-04-05Not applicableUs
Quetiapine FumarateTablet, film coated50 mg/1OralProficient Rx LP2012-03-26Not applicableUs
Quetiapine FumarateTablet25 mg/1OralAscend Laboratories, LLC2013-03-01Not applicableUs
Quetiapine FumarateTablet, film coated200 mg/1OralApotex Corp.2012-03-27Not applicableUs
Quetiapine FumarateTablet, film coated200 mg/1OralAurobindo Pharma Limited2012-03-27Not applicableUs
Quetiapine FumarateTablet, film coated200 mg/1OralPreferred Pharmaceuticals, Inc.2014-04-23Not applicableUs
Quetiapine FumarateTablet200 mg/1OralTorrent Pharmaceuticals Limited2012-03-27Not applicableUs
Quetiapine FumarateTablet, film coated200 mg/1OralMacleods Pharmaceuticals Limited2016-06-14Not applicableUs
Quetiapine FumarateTablet, film coated100 mg/1OralUnit Dose Services2012-03-26Not applicableUs
Quetiapine FumarateTablet, film coated50 mg/1OralNcs Health Care Of Ky, Inc Dba Vangard Labs2012-03-27Not applicableUs
Quetiapine FumarateTablet25 mg/1OralAv Pak2016-05-24Not applicableUs
Quetiapine FumarateTablet, film coated400 mg/1OralREMEDYREPACK INC.2014-05-282016-04-05Us
Quetiapine FumarateTablet200 mg/1OralREMEDYREPACK INC.2016-09-23Not applicableUs
Quetiapine FumarateTablet, film coated300 mg/1OralAmerican Health Packaging2012-04-02Not applicableUs
Quetiapine FumarateTablet, film coated25 mg/1OralAurobindo Pharma Limited2012-03-27Not applicableUs
Quetiapine FumarateTablet100 mg/1OralLupin Pharmaceuticals, Inc.2012-03-27Not applicableUs
Quetiapine FumarateTablet, film coated400 mg/1OralUnichem Pharmaceuticals (USA), Inc.2016-07-01Not applicableUs
Quetiapine FumarateTablet, film coated100 mg/1OralNorthstar Rx LLC2015-01-12Not applicableUs
Quetiapine FumarateTablet, film coated200 mg/1OralAphena Pharma Solutions Tennessee, Llc2014-01-17Not applicableUs
Quetiapine FumarateTablet, film coated25 mg/1OralREMEDYREPACK INC.2013-05-282016-04-05Us
Quetiapine FumarateTablet, film coated300 mg/1OralMajor Pharmaceuticals2014-06-16Not applicableUs
Quetiapine FumarateTablet, film coated300 mg/1OralDr.Reddy's Laboratories Limited2012-03-27Not applicableUs
Quetiapine FumarateTablet200 mg/1OralAphena Pharma Solutions Tennessee, Llc2012-03-27Not applicableUs
Quetiapine FumarateTablet50 mg/1OralWest Ward Pharmaceuticals Corp2012-03-27Not applicableUs
Quetiapine FumarateTablet, film coated25 mg/1OralREMEDYREPACK INC.2013-02-082016-10-13Us
Quetiapine FumarateTablet, film coated50 mg/1OralSun Pharma Global FZE2012-03-28Not applicableUs
Quetiapine FumarateTablet, film coated25 mg/1OralApotex Corp.2012-03-27Not applicableUs
Quetiapine FumarateTablet, film coated300 mg/1OralClinical Solutions Wholesale2012-03-28Not applicableUs
Quetiapine FumarateTablet100 mg/1OralSandoz Inc2013-04-05Not applicableUs
Quetiapine FumarateTablet50 mg/1OralREMEDYREPACK INC.2015-12-24Not applicableUs
Quetiapine FumarateTablet, film coated25 mg/1OralTYA Pharmaceuticals2012-03-26Not applicableUs
Quetiapine FumarateTablet, film coated100 mg/1Oralbryant ranch prepack2012-03-26Not applicableUs
Quetiapine FumarateTablet400 mg/1OralAscend Laboratories, LLC2013-03-01Not applicableUs
Quetiapine FumarateTablet, film coated400 mg/1OralApotex Corp.2012-03-27Not applicableUs
Quetiapine FumarateTablet400 mg/1OralBlue Point Laboratories2013-02-28Not applicableUs
Quetiapine FumarateTablet, film coated50 mg/1OralNcs Health Care Of Ky, Inc Dba Vangard Labs2012-03-26Not applicableUs
Quetiapine FumarateTablet, film coated50 mg/1OralNorth Star Rx Llc2012-03-272016-10-13Us
Quetiapine FumarateTablet400 mg/1OralAphena Pharma Solutions Tennessee, Llc2012-03-27Not applicableUs
Quetiapine FumarateTablet, film coated100 mg/1OralBreckenridge Pharmaceutical, Inc2012-03-26Not applicableUs
Quetiapine FumarateTablet, film coated400 mg/1OralNcs Health Care Of Ky, Inc Dba Vangard Labs2012-03-27Not applicableUs
Quetiapine FumarateTablet300 mg/1OralAv Pak2016-05-24Not applicableUs
Quetiapine FumarateTablet, film coated50 mg/1OralPhysicians Total Care, Inc.2012-04-02Not applicableUs
Quetiapine FumarateTablet, film coated100 mg/1OralGolden State Medical Supply, Inc.2015-07-21Not applicableUs
Quetiapine FumarateTablet, film coated300 mg/1OralAv Kare, Inc.2014-01-17Not applicableUs
Quetiapine FumarateTablet300 mg/1OralLUPIN LIMITED2012-03-27Not applicableUs
Quetiapine FumarateTablet, film coated300 mg/1OralAlembic Pharmaceuticals Limited2012-03-26Not applicableUs
Quetiapine FumarateTablet50 mg/1OralCardinal Health2013-03-01Not applicableUs
Quetiapine FumarateTablet, film coated300 mg/1OralCitron Pharma LLC2012-03-27Not applicableUs
Quetiapine FumarateTablet, film coated400 mg/1OralGolden State Medical Supply, Inc.2012-03-27Not applicableUs
Quetiapine FumarateTablet, film coated200 mg/1OralAphena Pharma Solutions Tennessee, Llc2012-03-27Not applicableUs
Quetiapine FumarateTablet100 mg/1OralWest Ward Pharmaceuticals Corp2012-03-27Not applicableUs
Quetiapine FumarateTablet, film coated200 mg/1OralREMEDYREPACK INC.2013-02-072016-10-13Us
Quetiapine FumarateTablet, film coated300 mg/1OralCardinal Health2012-04-02Not applicableUs
Quetiapine FumarateTablet, film coated25 mg/1OralClinical Solutions Wholesale2012-03-28Not applicableUs
Quetiapine FumarateTablet, extended release400 mg/1OralAccord Healthcare Inc.2016-11-01Not applicableUs
Quetiapine FumarateTablet400 mg/1OralREMEDYREPACK INC.2015-07-14Not applicableUs
Quetiapine FumarateTablet100 mg/1OralMc Kesson Packaging Services A Business Unit Of Mc Kesson Corporation2013-04-05Not applicableUs
Quetiapine FumarateTablet, film coated50 mg/1OralAmerican Health Packaging2012-04-02Not applicableUs
Quetiapine FumarateTablet100 mg/1OralREMEDYREPACK INC.2015-02-16Not applicableUs
Quetiapine FumarateTablet25 mg/1OralBlue Point Laboratories2013-02-28Not applicableUs
Quetiapine FumarateTablet, film coated100 mg/1OralUnichem Pharmaceuticals (USA), Inc.2016-07-01Not applicableUs
Quetiapine FumarateTablet, film coated400 mg/1OralNorth Star Rx Llc2012-03-272016-10-13Us
Quetiapine FumarateTablet, film coated100 mg/1OralAphena Pharma Solutions Tennessee, Llc2015-07-21Not applicableUs
Quetiapine FumarateTablet, film coated100 mg/1OralREMEDYREPACK INC.2013-03-28Not applicableUs
Quetiapine FumarateTablet, film coated100 mg/1OralMajor Pharmaceuticals2012-04-02Not applicableUs
Quetiapine FumarateTablet, film coated300 mg/1OralREMEDYREPACK INC.2016-07-20Not applicableUs
Quetiapine FumarateTablet, film coated100 mg/1OralDr.Reddy's Laboratories Limited2012-03-27Not applicableUs
Quetiapine FumarateTablet50 mg/1OralAv Pak2016-05-24Not applicableUs
Quetiapine FumarateTablet50 mg/1OralREMEDYREPACK INC.2014-07-09Not applicableUs
Quetiapine FumarateTablet100 mg/1OralREMEDYREPACK INC.2016-10-07Not applicableUs
Quetiapine FumarateTablet, film coated50 mg/1OralAvera Mc Kennan Hospital2015-03-01Not applicableUs
Quetiapine FumarateTablet, film coated50 mg/1OralAv Kare, Inc.2014-01-17Not applicableUs
Quetiapine FumarateTablet50 mg/1OralLUPIN LIMITED2012-03-27Not applicableUs
Quetiapine FumarateTablet, film coated50 mg/1OralAlembic Pharmaceuticals Limited2012-03-26Not applicableUs
Quetiapine FumarateTablet, film coated100 mg/1OralREMEDYREPACK INC.2012-04-13Not applicableUs
Quetiapine FumarateTablet, film coated200 mg/1OralCardinal Health2012-04-02Not applicableUs
Quetiapine FumarateTablet, film coated50 mg/1OralCitron Pharma LLC2012-03-27Not applicableUs
Quetiapine FumarateTablet, film coated100 mg/1OralGolden State Medical Supply, Inc.2012-03-27Not applicableUs
Quetiapine FumarateTablet25 mg/1OralNu Care Pharmaceuticals, Inc.2013-03-01Not applicableUs
Quetiapine FumarateTablet, film coated100 mg/1OralProficient Rx LP2012-03-26Not applicableUs
Quetiapine FumarateTablet150 mg/1OralAscend Laboratories, LLC2013-03-01Not applicableUs
Quetiapine FumarateTablet, film coated200 mg/1OralApotex Corp.2012-03-27Not applicableUs
Quetiapine FumarateTablet, film coated300 mg/1OralAurobindo Pharma Limited2012-03-27Not applicableUs
Quetiapine FumarateTablet300 mg/1OralPreferred Pharmaceuticals, Inc.2014-03-31Not applicableUs
Quetiapine FumarateTablet300 mg/1OralTorrent Pharmaceuticals Limited2012-03-27Not applicableUs
Quetiapine FumarateTablet, film coated300 mg/1OralMacleods Pharmaceuticals Limited2016-06-14Not applicableUs
Quetiapine FumarateTablet, film coated25 mg/1OralUnit Dose Services2012-03-26Not applicableUs
Quetiapine FumarateTablet, film coated100 mg/1OralNcs Health Care Of Ky, Inc Dba Vangard Labs2012-03-27Not applicableUs
Quetiapine FumarateTablet25 mg/1OralREMEDYREPACK INC.2015-12-24Not applicableUs
Quetiapine FumarateTablet, film coated100 mg/1OralTYA Pharmaceuticals2012-03-26Not applicableUs
Quetiapine FumarateTablet, film coated400 mg/1OralAmerican Health Packaging2012-04-02Not applicableUs
Quetiapine FumarateTablet, film coated50 mg/1OralAurobindo Pharma Limited2012-03-27Not applicableUs
Quetiapine FumarateTablet200 mg/1OralLupin Pharmaceuticals, Inc.2012-03-27Not applicableUs
Quetiapine FumarateTablet, film coated25 mg/1OralMacleods Pharmaceuticals Limited2016-06-14Not applicableUs
Quetiapine FumarateTablet, film coated200 mg/1OralNorthstar Rx LLC2015-01-12Not applicableUs
Quetiapine FumarateTablet, film coated100 mg/1OralREMEDYREPACK INC.2013-05-292016-10-13Us
Quetiapine FumarateTablet25 mg/1OralTorrent Pharmaceuticals Limited2012-03-27Not applicableUs
Quetiapine FumarateTablet, film coated25 mg/1OralDr.Reddy's Laboratories Limited2012-03-27Not applicableUs
Quetiapine FumarateTablet, film coated400 mg/1OralREMEDYREPACK INC.2016-01-29Not applicableUs
Quetiapine FumarateTablet100 mg/1OralAphena Pharma Solutions Tennessee, Llc2012-03-27Not applicableUs
Quetiapine FumarateTablet400 mg/1OralWest Ward Pharmaceuticals Corp2012-03-27Not applicableUs
Quetiapine FumarateTablet, film coated200 mg/1OralREMEDYREPACK INC.2013-02-152016-10-13Us
Quetiapine FumarateTablet, film coated100 mg/1OralSun Pharma Global FZE2012-03-28Not applicableUs
Quetiapine FumarateTablet, film coated50 mg/1OralApotex Corp.2012-03-27Not applicableUs
Quetiapine FumarateTablet, film coated400 mg/1OralClinical Solutions Wholesale2012-03-28Not applicableUs
Quetiapine FumarateTablet150 mg/1OralSandoz Inc2013-04-05Not applicableUs
Quetiapine FumarateTablet200 mg/1OralCardinal Health2013-03-01Not applicableUs
Quetiapine FumarateTablet, film coated400 mg/1OralCitron Pharma LLC2012-03-27Not applicableUs
Quetiapine FumarateTablet, film coated200 mg/1OralREMEDYREPACK INC.2014-10-08Not applicableUs
Quetiapine FumarateTablet, film coated50 mg/1Oralbryant ranch prepack2012-03-26Not applicableUs
Quetiapine FumarateTablet50 mg/1OralAscend Laboratories, LLC2013-03-01Not applicableUs
Quetiapine FumarateTablet200 mg/1OralREMEDYREPACK INC.2014-10-07Not applicableUs
Quetiapine FumarateTablet200 mg/1OralBlue Point Laboratories2013-02-28Not applicableUs
Quetiapine FumarateTablet, film coated100 mg/1OralNcs Health Care Of Ky, Inc Dba Vangard Labs2012-03-26Not applicableUs
Quetiapine FumarateTablet, film coated100 mg/1OralNorth Star Rx Llc2012-03-272016-10-13Us
Quetiapine FumarateTablet, film coated100 mg/1OralAphena Pharma Solutions Tennessee, Llc2014-01-17Not applicableUs
Quetiapine FumarateTablet, film coated200 mg/1OralBreckenridge Pharmaceutical, Inc2012-03-26Not applicableUs
Quetiapine FumarateTablet, film coated25 mg/1OralNcs Health Care Of Ky, Inc Dba Vangard Labs2013-07-17Not applicableUs
Quetiapine FumarateTablet400 mg/1OralAv Pak2016-05-24Not applicableUs
Quetiapine FumarateTablet, film coated200 mg/1OralPhysicians Total Care, Inc.2012-04-02Not applicableUs
Quetiapine FumarateTablet, film coated200 mg/1OralGolden State Medical Supply, Inc.2015-07-21Not applicableUs
Quetiapine FumarateTablet, film coated400 mg/1OralAv Kare, Inc.2014-01-17Not applicableUs
Quetiapine FumarateTablet400 mg/1OralLUPIN LIMITED2012-03-27Not applicableUs
Quetiapine FumarateTablet, film coated400 mg/1OralAlembic Pharmaceuticals Limited2012-03-26Not applicableUs
Quetiapine FumarateTablet, film coated25 mg/1OralCardinal Health2012-04-02Not applicableUs
Quetiapine FumarateTablet, film coated200 mg/1OralAphena Pharma Solutions Tennessee, Llc2015-07-21Not applicableUs
Quetiapine FumarateTablet, film coated200 mg/1OralREMEDYREPACK INC.2013-03-28Not applicableUs
Quetiapine FumarateTablet, film coated200 mg/1OralMajor Pharmaceuticals2012-04-02Not applicableUs
Quetiapine FumarateTablet, film coated150 mg/1OralDr.Reddy's Laboratories Limited2012-03-27Not applicableUs
Quetiapine FumarateTablet, film coated200 mg/1OralLake Erie Medical DBA Quality Care Products LLC2012-03-28Not applicableUs
Quetiapine FumarateTablet, film coated25 mg/1OralAphena Pharma Solutions Tennessee, Llc2012-03-27Not applicableUs
Quetiapine FumarateTablet200 mg/1OralWest Ward Pharmaceuticals Corp2012-03-27Not applicableUs
Quetiapine FumarateTablet, film coated300 mg/1OralREMEDYREPACK INC.2013-02-182016-10-13Us
Quetiapine FumarateTablet200 mg/1OralClinical Solutions Wholesale, Llc2012-03-27Not applicableUs
Quetiapine FumarateTablet, film coated50 mg/1OralClinical Solutions Wholesale2012-03-28Not applicableUs
Quetiapine FumarateTablet50 mg/1OralSandoz Inc2013-04-05Not applicableUs
Quetiapine FumarateTablet, film coated300 mg/1OralREMEDYREPACK INC.2015-08-31Not applicableUs
Quetiapine FumarateTablet200 mg/1OralMc Kesson Packaging Services A Business Unit Of Mc Kesson Corporation2013-04-05Not applicableUs
Quetiapine FumarateTablet, film coated100 mg/1OralAmerican Health Packaging2012-04-02Not applicableUs
Quetiapine FumarateTablet, film coated200 mg/1OralREMEDYREPACK INC.2015-03-10Not applicableUs
Quetiapine FumarateTablet25 mg/1OralLupin Pharmaceuticals, Inc.2012-03-27Not applicableUs
Quetiapine FumarateTablet, film coated200 mg/1OralUnichem Pharmaceuticals (USA), Inc.2016-07-01Not applicableUs
Quetiapine FumarateTablet, film coated25 mg/1OralNorthstar Rx LLC2015-01-12Not applicableUs
Quetiapine FumarateTablet, film coated25 mg/1OralREMEDYREPACK INC.2016-01-20Not applicableUs
Quetiapine FumarateTablet400 mg/1OralTorrent Pharmaceuticals Limited2012-03-27Not applicableUs
Quetiapine FumarateTablet, film coated400 mg/1OralMacleods Pharmaceuticals Limited2016-06-14Not applicableUs
Quetiapine FumarateTablet, film coated25 mg/1OralBreckenridge Pharmaceutical, Inc2012-03-26Not applicableUs
Quetiapine FumarateTablet, film coated200 mg/1OralNcs Health Care Of Ky, Inc Dba Vangard Labs2012-03-27Not applicableUs
Quetiapine FumarateTablet100 mg/1OralAv Pak2016-05-24Not applicableUs
Quetiapine FumarateTablet, film coated100 mg/1OralPhysicians Total Care, Inc.2012-04-02Not applicableUs
Quetiapine FumarateTablet, film coated300 mg/1OralTYA Pharmaceuticals2012-03-26Not applicableUs
Quetiapine FumarateTablet, film coated25 mg/1OralGolden State Medical Supply, Inc.2015-07-21Not applicableUs
Quetiapine FumarateTablet, film coated100 mg/1OralAv Kare, Inc.2014-01-17Not applicableUs
Quetiapine FumarateTablet100 mg/1OralLUPIN LIMITED2012-03-27Not applicableUs
Quetiapine FumarateTablet, film coated100 mg/1OralAlembic Pharmaceuticals Limited2012-03-26Not applicableUs
Quetiapine FumarateTablet, film coated400 mg/1OralREMEDYREPACK INC.2012-08-23Not applicableUs
Quetiapine FumarateTablet25 mg/1OralCardinal Health2013-03-01Not applicableUs
Quetiapine FumarateTablet, film coated100 mg/1OralCitron Pharma LLC2012-03-27Not applicableUs
Quetiapine FumarateTablet, film coated200 mg/1OralGolden State Medical Supply, Inc.2012-03-27Not applicableUs
Quetiapine FumarateTablet, film coated400 mg/1OralREMEDYREPACK INC.2016-11-17Not applicableUs
Quetiapine FumarateTablet, film coated25 mg/1OralProficient Rx LP2012-03-26Not applicableUs
Quetiapine FumarateTablet200 mg/1OralAscend Laboratories, LLC2013-03-01Not applicableUs
Quetiapine FumarateTablet, film coated300 mg/1OralApotex Corp.2012-03-27Not applicableUs
Quetiapine FumarateTablet, film coated400 mg/1OralAurobindo Pharma Limited2012-03-27Not applicableUs
Quetiapine FumarateTablet, film coated100 mg/1OralClinical Solutions Wholesale2012-03-28Not applicableUs
Quetiapine FumarateTablet200 mg/1OralSandoz Inc2013-04-05Not applicableUs
Quetiapine FumarateTablet, film coated25 mg/1OralDIRECT RX2015-01-01Not applicableUs
Quetiapine FumarateTablet, film coated200 mg/1OralTYA Pharmaceuticals2012-03-26Not applicableUs
Quetiapine FumarateTablet25 mg/1OralAvera Mc Kennan Hospital2015-03-09Not applicableUs
Quetiapine FumarateTablet, film coated100 mg/1OralAurobindo Pharma Limited2012-03-27Not applicableUs
Quetiapine FumarateTablet300 mg/1OralLupin Pharmaceuticals, Inc.2012-03-27Not applicableUs
Quetiapine FumarateTablet, film coated50 mg/1OralMacleods Pharmaceuticals Limited2016-06-14Not applicableUs
Quetiapine FumarateTablet, film coated300 mg/1OralNorthstar Rx LLC2015-01-12Not applicableUs
Quetiapine FumarateTablet, film coated200 mg/1OralREMEDYREPACK INC.2013-05-292016-04-05Us
Quetiapine FumarateTablet50 mg/1OralTorrent Pharmaceuticals Limited2012-03-27Not applicableUs
Quetiapine FumarateTablet, film coated400 mg/1OralDr.Reddy's Laboratories Limited2012-03-27Not applicableUs
Quetiapine FumarateTablet, film coated200 mg/1OralREMEDYREPACK INC.2016-01-29Not applicableUs
Quetiapine FumarateTablet, film coated300 mg/1OralAphena Pharma Solutions Tennessee, Llc2012-03-27Not applicableUs
Quetiapine FumarateTablet, film coated300 mg/1OralREMEDYREPACK INC.2013-02-082016-10-13Us
Quetiapine FumarateTablet, film coated200 mg/1OralSun Pharma Global FZE2012-03-28Not applicableUs
Quetiapine FumarateTablet, film coated100 mg/1OralApotex Corp.2012-03-27Not applicableUs
Quetiapine FumarateTablet300 mg/1OralCardinal Health2013-03-01Not applicableUs
Quetiapine FumarateTablet, film coated50 mg/1OralREMEDYREPACK INC.2015-05-26Not applicableUs
Quetiapine FumarateTablet, film coated25 mg/1Oralbryant ranch prepack2012-03-26Not applicableUs
Quetiapine FumarateTablet100 mg/1OralAscend Laboratories, LLC2013-03-01Not applicableUs
Quetiapine FumarateTablet, film coated100 mg/1OralREMEDYREPACK INC.2014-10-08Not applicableUs
Quetiapine FumarateTablet300 mg/1OralBlue Point Laboratories2013-02-28Not applicableUs
Quetiapine FumarateTablet, film coated25 mg/1OralUnichem Pharmaceuticals (USA), Inc.2016-07-01Not applicableUs
Quetiapine FumarateTablet, film coated200 mg/1OralNorth Star Rx Llc2012-03-272016-10-13Us
Quetiapine FumarateTablet, film coated300 mg/1OralAphena Pharma Solutions Tennessee, Llc2015-07-21Not applicableUs
Quetiapine FumarateTablet, film coated300 mg/1OralBreckenridge Pharmaceutical, Inc2012-03-26Not applicableUs
Quetiapine FumarateTablet, film coated25 mg/1OralMajor Pharmaceuticals2012-04-02Not applicableUs
Quetiapine FumarateTablet, film coated300 mg/1OralREMEDYREPACK INC.2016-04-20Not applicableUs
Quetiapine FumarateTablet, film coated300 mg/1OralPhysicians Total Care, Inc.2012-04-12Not applicableUs
Quetiapine FumarateTablet, film coated100 mg/1OralA S Medication Solutions2015-01-12Not applicableUs
Quetiapine FumarateTablet, film coated300 mg/1OralGolden State Medical Supply, Inc.2015-07-21Not applicableUs
Quetiapine FumarateTablet, film coated50 mg/1OralSTAT Rx USA LLC2012-03-26Not applicableUs
Quetiapine FumarateTablet, film coated100 mg/1OralMc Kesson Contract Packaging2012-03-27Not applicableUs
Quetiapine FumarateTablet, film coated25 mg/1OralSafecor Health, LLC2014-09-30Not applicableUs
Quetiapine FumarateTablet, film coated100 mg/1OralCardinal Health2012-04-02Not applicableUs
Quetiapine FumarateTablet50 mg/1OralLupin Pharmaceuticals, Inc.2012-03-27Not applicableUs
Quetiapine FumarateTablet, film coated300 mg/1OralUnichem Pharmaceuticals (USA), Inc.2016-07-01Not applicableUs
Quetiapine FumarateTablet, film coated50 mg/1OralNorthstar Rx LLC2015-01-12Not applicableUs
Quetiapine FumarateTablet, film coated300 mg/1OralAphena Pharma Solutions Tennessee, Llc2014-01-17Not applicableUs
Quetiapine FumarateTablet, film coated200 mg/1OralREMEDYREPACK INC.2013-05-132016-10-13Us
Quetiapine FumarateTablet, film coated400 mg/1OralMajor Pharmaceuticals2012-04-02Not applicableUs
Quetiapine FumarateTablet, film coated200 mg/1OralREMEDYREPACK INC.2016-08-12Not applicableUs
Quetiapine FumarateTablet, film coated200 mg/1OralDr.Reddy's Laboratories Limited2012-03-27Not applicableUs
Quetiapine FumarateTablet25 mg/1OralAphena Pharma Solutions Tennessee, Llc2012-03-27Not applicableUs
Quetiapine FumarateTablet300 mg/1OralWest Ward Pharmaceuticals Corp2012-03-27Not applicableUs
Quetiapine FumarateTablet, film coated50 mg/1OralREMEDYREPACK INC.2013-02-152016-10-13Us
Quetiapine FumarateTablet, film coated25 mg/1OralSun Pharma Global FZE2012-03-28Not applicableUs
Quetiapine FumarateTablet, film coated25 mg/1OralApotex Corp.2012-03-27Not applicableUs
Quetiapine FumarateTablet, film coated200 mg/1OralClinical Solutions Wholesale2012-03-28Not applicableUs
Quetiapine FumarateTablet25 mg/1OralSandoz Inc2013-04-05Not applicableUs
Quetiapine FumarateTablet50 mg/1OralREMEDYREPACK INC.2015-10-27Not applicableUs
Quetiapine FumarateTablet300 mg/1OralMc Kesson Packaging Services A Business Unit Of Mc Kesson Corporation2013-04-05Not applicableUs
Quetiapine FumarateTablet, film coated200 mg/1OralAmerican Health Packaging2012-04-02Not applicableUs
Quetiapine FumarateTablet300 mg/1OralREMEDYREPACK INC.2015-07-15Not applicableUs
Quetiapine FumarateTablet, film coated300 mg/1OralApotex Corp.2012-03-27Not applicableUs
Quetiapine FumarateTablet50 mg/1OralBlue Point Laboratories2013-02-28Not applicableUs
Quetiapine FumarateTablet, film coated25 mg/1OralNcs Health Care Of Ky, Inc Dba Vangard Labs2012-03-26Not applicableUs
Quetiapine FumarateTablet, film coated25 mg/1OralNorth Star Rx Llc2012-03-272016-10-13Us
Quetiapine FumarateTablet300 mg/1OralAphena Pharma Solutions Tennessee, Llc2012-03-27Not applicableUs
Quetiapine FumarateTablet, film coated50 mg/1OralBreckenridge Pharmaceutical, Inc2012-03-26Not applicableUs
Quetiapine FumarateTablet, film coated300 mg/1OralNcs Health Care Of Ky, Inc Dba Vangard Labs2012-03-27Not applicableUs
Quetiapine FumarateTablet200 mg/1OralAv Pak2016-05-24Not applicableUs
Quetiapine FumarateTablet, film coated25 mg/1OralPhysicians Total Care, Inc.2012-04-02Not applicableUs
Quetiapine FumarateTablet, film coated400 mg/1OralA S Medication Solutions2015-01-12Not applicableUs
Quetiapine FumarateTablet, film coated50 mg/1OralGolden State Medical Supply, Inc.2015-07-21Not applicableUs
Quetiapine FumarateTablet, film coated200 mg/1OralAv Kare, Inc.2014-01-17Not applicableUs
Quetiapine FumarateTablet200 mg/1OralLUPIN LIMITED2012-03-27Not applicableUs
Quetiapine FumarateTablet, film coated200 mg/1OralAlembic Pharmaceuticals Limited2012-03-26Not applicableUs
Quetiapine FumarateTablet, film coated100 mg/1OralREMEDYREPACK INC.2013-09-24Not applicableUs
Quetiapine FumarateTablet100 mg/1OralCardinal Health2013-03-01Not applicableUs
Quetiapine FumarateTablet, film coated200 mg/1OralCitron Pharma LLC2012-03-27Not applicableUs
Quetiapine FumarateTablet, film coated300 mg/1OralGolden State Medical Supply, Inc.2012-03-27Not applicableUs
Quetiapine FumarateTablet, film coated200 mg/1Oralbryant ranch prepack2012-03-26Not applicableUs
Quetiapine FumarateTablet300 mg/1OralAscend Laboratories, LLC2013-03-01Not applicableUs
Quetiapine FumarateTablet, film coated100 mg/1OralApotex Corp.2012-03-27Not applicableUs
Quetiapine FumarateTablet, film coated25 mg/1OralGolden State Medical Supply, Inc.2012-03-27Not applicableUs
Quetiapine FumarateTablet300 mg/1OralSandoz Inc2013-04-05Not applicableUs
Quetiapine FumarateTablet, film coated50 mg/1OralDIRECT RX2015-01-01Not applicableUs
Quetiapine FumarateTablet, film coated50 mg/1OralTYA Pharmaceuticals2012-03-27Not applicableUs
Quetiapine FumarateTablet, film coated100 mg/1OralAvera Mc Kennan Hospital2015-04-16Not applicableUs
Quetiapine FumarateTablet, film coated150 mg/1OralAurobindo Pharma Limited2012-03-27Not applicableUs
Quetiapine FumarateTablet400 mg/1OralLupin Pharmaceuticals, Inc.2012-03-27Not applicableUs
Quetiapine FumarateTablet, film coated100 mg/1OralMacleods Pharmaceuticals Limited2016-06-14Not applicableUs
Quetiapine FumarateTablet, film coated400 mg/1OralNorthstar Rx LLC2015-01-12Not applicableUs
Quetiapine FumarateTablet, film coated400 mg/1OralREMEDYREPACK INC.2014-05-28Not applicableUs
Quetiapine FumarateTablet100 mg/1OralTorrent Pharmaceuticals Limited2012-03-27Not applicableUs
Quetiapine FumarateTablet, film coated25 mg/1OralCardinal Health2012-04-02Not applicableUs
Quetiapine FumarateTablet25 mg/1OralJubilant Cadista Pharmaceuticals Inc.2013-11-27Not applicableUs
Quetiapine FumarateTablet, film coated400 mg/1OralAphena Pharma Solutions Tennessee, Llc2012-03-27Not applicableUs
Quetiapine FumarateTablet, film coated400 mg/1OralREMEDYREPACK INC.2013-02-082016-10-13Us
Quetiapine FumarateTablet, film coated300 mg/1OralSun Pharma Global FZE2012-03-28Not applicableUs
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International BrandsNot Available
Brand mixturesNot Available
SaltsNot Available
Categories
UNIIBGL0JSY5SI
CAS number111974-69-7
WeightAverage: 383.507
Monoisotopic: 383.166747749
Chemical FormulaC21H25N3O2S
InChI KeyURKOMYMAXPYINW-UHFFFAOYSA-N
InChI
InChI=1S/C21H25N3O2S/c25-14-16-26-15-13-23-9-11-24(12-10-23)21-17-5-1-3-7-19(17)27-20-8-4-2-6-18(20)22-21/h1-8,25H,9-16H2
IUPAC Name
2-[2-(4-{2-thia-9-azatricyclo[9.4.0.0³,⁸]pentadeca-1(15),3,5,7,9,11,13-heptaen-10-yl}piperazin-1-yl)ethoxy]ethan-1-ol
SMILES
OCCOCCN1CCN(CC1)C1=NC2=CC=CC=C2SC2=CC=CC=C12
Pharmacology
IndicationFor the treatment of schizophrenia and related psychotic disorders.
Structured Indications
PharmacodynamicsQuetiapine is a psychotropic agent belonging to the chemical class of benzisoxazole derivatives and is indicated for the treatment of schizophrenia. Quetiapine is a selective monoaminergic antagonist with high affinity for the serotonin Type 2 (5HT2), and dopamine type 2 (D2) receptors. Quetiapine is an antagonist at serotonin 5-HT1A and 5HT2, dopamine D1 and D2, histamine H1, and adrenergic alpha 1 and alpha 2 receptors. Quetiapine has no significant affinity for cholinergic muscarinic or benzodiazepine receptors. Drowsiness and orthostatic hypotension associated with use of quetiapine may be explained by its antagonism of histamine H1 and adrenergic alpha 1 receptors, respectively. Quetiapine's antagonism of adrenergic a1 receptors may explain the orthostatic hypotension observed with this drug.
Mechanism of actionQuetiapine's antipsychotic activity is likely due to a combination of antagonism at D2 receptors in the mesolimbic pathway and 5HT2A receptors in the frontal cortex. Antagonism at D2 receptors relieves positive symptoms while antagonism at 5HT2A receptors relieves negative symptoms of schizophrenia.
TargetKindPharmacological actionActionsOrganismUniProt ID
5-hydroxytryptamine receptor 2AProteinyes
antagonist
HumanP28223 details
D(2) dopamine receptorProteinyes
antagonist
HumanP14416 details
5-hydroxytryptamine receptor 1AProteinunknown
antagonist
HumanP08908 details
5-hydroxytryptamine receptor 1BProteinunknown
other/unknown
HumanP28222 details
5-hydroxytryptamine receptor 1DProteinunknown
other/unknown
HumanP28221 details
5-hydroxytryptamine receptor 1EProteinunknown
other/unknown
HumanP28566 details
5-hydroxytryptamine receptor 2CProteinunknown
antagonist
HumanP28335 details
5-hydroxytryptamine receptor 3AProteinunknown
other/unknown
HumanP46098 details
5-hydroxytryptamine receptor 6Proteinunknown
other/unknown
HumanP50406 details
5-hydroxytryptamine receptor 7Proteinunknown
antagonist
HumanP34969 details
D(1A) dopamine receptorProteinunknown
antagonist
HumanP21728 details
D(1B) dopamine receptorProteinunknown
antagonist
HumanP21918 details
D(3) dopamine receptorProteinunknown
antagonist
HumanP35462 details
D(4) dopamine receptorProteinunknown
antagonist
HumanP21917 details
Histamine H1 receptorProteinunknown
antagonist
HumanP35367 details
Alpha-1A adrenergic receptorProteinunknown
antagonist
HumanP35348 details
Alpha-1B adrenergic receptorProteinunknown
antagonist
HumanP35368 details
Alpha-1D adrenergic receptorProteinunknown
antagonist
HumanP25100 details
Alpha-2A adrenergic receptorProteinunknown
antagonist
HumanP08913 details
Alpha-2B adrenergic receptorProteinunknown
antagonist
HumanP18089 details
Alpha-2C adrenergic receptorProteinunknown
antagonist
HumanP18825 details
Muscarinic acetylcholine receptor M1Proteinunknown
antagonist
HumanP11229 details
Muscarinic acetylcholine receptor M2Proteinunknown
antagonist
HumanP08172 details
Muscarinic acetylcholine receptor M3Proteinunknown
antagonist
HumanP20309 details
Muscarinic acetylcholine receptor M4Proteinunknown
antagonist
HumanP08173 details
Muscarinic acetylcholine receptor M5Proteinunknown
antagonist
HumanP08912 details
Related Articles
AbsorptionRapidly and well absorbed.
Volume of distribution
  • 10±4 L/kg
Protein binding83%
Metabolism

Hepatic. The major metabolic pathways are sulfoxidation, mediated by cytochrome P450 3A4 (CYP3A4), and oxidation of the terminal alcohol to a carboxylic acid. The major sulfoxide metabolite of quetiapine is inactive. Quetiapine also undergoes hydroxylation of the dibenzothiazepine ring, O-deakylation, N-dealkylation, and phase II conjugation. The 7-hydroxy and 7-hydroxy- N-delakylated metabolites appear to be active, but are present in very low concentrations.

Route of eliminationElimination of quetiapine is mainly via hepatic metabolism. Following a single oral dose of 14C-quetiapine, less than 1% of the administered dose was excreted as unchanged drug, indicating that quetiapine is highly metabolized. Approximately 73% and 20% of the dose was recovered in the urine and feces, respectively.
Half life6 hours
ClearanceNot Available
ToxicitySymptoms of overdose include drowsiness and sedation, tachycardia, and hypotension.
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
Interactions
Drug Interactions
DrugInteractionDrug group
1,1,1,2 TetrafluoroethaneThe risk or severity of adverse effects can be increased when Quetiapine is combined with 1,1,1,2 Tetrafluoroethane.Investigational
2,5-Dimethoxy-4-ethylamphetamineQuetiapine may decrease the stimulatory activities of 2,5-Dimethoxy-4-ethylamphetamine.Experimental, Illicit
3,4-MethylenedioxyamphetamineQuetiapine may decrease the stimulatory activities of 3,4-Methylenedioxyamphetamine.Experimental, Illicit
3,4-MethylenedioxymethamphetamineQuetiapine may decrease the stimulatory activities of 3,4-Methylenedioxymethamphetamine.Experimental, Illicit
4-Bromo-2,5-dimethoxyamphetamineQuetiapine may decrease the stimulatory activities of 4-Bromo-2,5-dimethoxyamphetamine.Experimental, Illicit
7-NitroindazoleThe risk or severity of adverse effects can be increased when Quetiapine is combined with 7-Nitroindazole.Experimental
AbirateroneThe serum concentration of Quetiapine can be increased when it is combined with Abiraterone.Approved
AcarboseThe therapeutic efficacy of Acarbose can be decreased when used in combination with Quetiapine.Approved, Investigational
AcebutololThe risk or severity of adverse effects can be increased when Acebutolol is combined with Quetiapine.Approved
AcepromazineThe risk or severity of adverse effects can be increased when Quetiapine is combined with Acepromazine.Approved, Vet Approved
AceprometazineThe risk or severity of adverse effects can be increased when Quetiapine is combined with Aceprometazine.Approved
AcetaminophenThe serum concentration of Quetiapine can be increased when it is combined with Acetaminophen.Approved
AcetazolamideThe risk or severity of adverse effects can be increased when Quetiapine is combined with Acetazolamide.Approved, Vet Approved
AcetohexamideThe therapeutic efficacy of Acetohexamide can be decreased when used in combination with Quetiapine.Withdrawn
adipiplonThe risk or severity of adverse effects can be increased when Quetiapine is combined with adipiplon.Investigational
AfatinibThe serum concentration of Quetiapine can be increased when it is combined with Afatinib.Approved
AgomelatineThe risk or severity of adverse effects can be increased when Quetiapine is combined with Agomelatine.Approved, Investigational
AicarThe therapeutic efficacy of Aicar can be decreased when used in combination with Quetiapine.Experimental
AlbendazoleThe serum concentration of Quetiapine can be increased when it is combined with Albendazole.Approved, Vet Approved
AldesleukinThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Quetiapine.Approved
AldosteroneThe serum concentration of Quetiapine can be decreased when it is combined with Aldosterone.Experimental
AlectinibThe serum concentration of Quetiapine can be increased when it is combined with Alectinib.Approved
AlfaxaloneThe risk or severity of adverse effects can be increased when Quetiapine is combined with Alfaxalone.Vet Approved
AlfentanilThe serum concentration of Quetiapine can be increased when it is combined with Alfentanil.Approved, Illicit
AlfuzosinAlfuzosin may increase the QTc-prolonging activities of Quetiapine.Approved, Investigational
AliskirenThe risk or severity of adverse effects can be increased when Quetiapine is combined with Aliskiren.Approved, Investigational
AlmotriptanThe risk or severity of adverse effects can be increased when Almotriptan is combined with Quetiapine.Approved, Investigational
AlogliptinThe therapeutic efficacy of Alogliptin can be decreased when used in combination with Quetiapine.Approved
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Quetiapine is combined with Alphacetylmethadol.Experimental, Illicit
AlprazolamThe risk or severity of adverse effects can be increased when Alprazolam is combined with Quetiapine.Approved, Illicit, Investigational
AmantadineAmantadine may increase the QTc-prolonging activities of Quetiapine.Approved
AmifostineThe risk or severity of adverse effects can be increased when Quetiapine is combined with Amifostine.Approved, Investigational
AmilorideThe risk or severity of adverse effects can be increased when Amiloride is combined with Quetiapine.Approved
Aminohippuric acidThe serum concentration of Quetiapine can be increased when it is combined with Aminohippuric acid.Approved
AmiodaroneThe serum concentration of Quetiapine can be increased when it is combined with Amiodarone.Approved, Investigational
AmisulprideThe risk or severity of adverse effects can be increased when Quetiapine is combined with Amisulpride.Approved, Investigational
AmitriptylineAmitriptyline may increase the QTc-prolonging activities of Quetiapine.Approved
AmlodipineThe risk or severity of adverse effects can be increased when Amlodipine is combined with Quetiapine.Approved
AmobarbitalThe risk or severity of adverse effects can be increased when Quetiapine is combined with Amobarbital.Approved, Illicit
AmoxapineAmoxapine may increase the QTc-prolonging activities of Quetiapine.Approved
AmperozideThe risk or severity of adverse effects can be increased when Quetiapine is combined with Amperozide.Experimental
AmphetamineQuetiapine may decrease the stimulatory activities of Amphetamine.Approved, Illicit
Amphotericin BThe risk or severity of adverse effects can be increased when Quetiapine is combined with Amphotericin B.Approved, Investigational
AmprenavirThe serum concentration of Quetiapine can be decreased when it is combined with Amprenavir.Approved
AmsacrineThe serum concentration of Quetiapine can be increased when it is combined with Amsacrine.Approved
Amyl NitriteThe risk or severity of adverse effects can be increased when Quetiapine is combined with Amyl Nitrite.Approved
AnagrelideAnagrelide may increase the QTc-prolonging activities of Quetiapine.Approved
ApomorphineApomorphine may increase the QTc-prolonging activities of Quetiapine.Approved, Investigational
ApraclonidineThe risk or severity of adverse effects can be increased when Apraclonidine is combined with Quetiapine.Approved
AprepitantThe serum concentration of Quetiapine can be increased when it is combined with Aprepitant.Approved, Investigational
ArformoterolArformoterol may increase the QTc-prolonging activities of Quetiapine.Approved, Investigational
AripiprazoleAripiprazole may increase the hypotensive activities of Quetiapine.Approved, Investigational
ArmodafinilThe metabolism of Quetiapine can be decreased when combined with Armodafinil.Approved, Investigational
ArotinololThe risk or severity of adverse effects can be increased when Quetiapine is combined with Arotinolol.Approved
Arsenic trioxideArsenic trioxide may increase the QTc-prolonging activities of Quetiapine.Approved, Investigational
ArtemetherQuetiapine may increase the QTc-prolonging activities of Artemether.Approved
ArticaineThe risk or severity of adverse effects can be increased when Quetiapine is combined with Articaine.Approved
AsenapineQuetiapine may increase the QTc-prolonging activities of Asenapine.Approved
AstemizoleThe serum concentration of Quetiapine can be increased when it is combined with Astemizole.Approved, Withdrawn
AtazanavirThe serum concentration of Quetiapine can be increased when it is combined with Atazanavir.Approved, Investigational
AtenololThe risk or severity of adverse effects can be increased when Atenolol is combined with Quetiapine.Approved
AtomoxetineAtomoxetine may increase the QTc-prolonging activities of Quetiapine.Approved
AtorvastatinThe serum concentration of Quetiapine can be increased when it is combined with Atorvastatin.Approved
AzaperoneThe risk or severity of adverse effects can be increased when Quetiapine is combined with Azaperone.Vet Approved
AzelastineQuetiapine may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved
AzelastineThe serum concentration of Quetiapine can be increased when it is combined with Azelastine.Approved
Azilsartan medoxomilThe risk or severity of adverse effects can be increased when Quetiapine is combined with Azilsartan medoxomil.Approved
AzithromycinAzithromycin may increase the QTc-prolonging activities of Quetiapine.Approved
BaclofenThe risk or severity of adverse effects can be increased when Quetiapine is combined with Baclofen.Approved
BalaglitazoneThe therapeutic efficacy of Balaglitazone can be decreased when used in combination with Quetiapine.Investigational
BarbexacloneBarbexaclone may increase the hypotensive activities of Quetiapine.Experimental
BarbitalThe risk or severity of adverse effects can be increased when Quetiapine is combined with Barbital.Illicit
BarnidipineThe risk or severity of adverse effects can be increased when Quetiapine is combined with Barnidipine.Approved
BedaquilineBedaquiline may increase the QTc-prolonging activities of Quetiapine.Approved
BenazeprilThe risk or severity of adverse effects can be increased when Benazepril is combined with Quetiapine.Approved, Investigational
BendroflumethiazideThe risk or severity of adverse effects can be increased when Bendroflumethiazide is combined with Quetiapine.Approved
BenperidolThe risk or severity of adverse effects can be increased when Quetiapine is combined with Benperidol.Investigational
BenzocaineThe serum concentration of Quetiapine can be increased when it is combined with Benzocaine.Approved
BenzphetamineQuetiapine may decrease the stimulatory activities of Benzphetamine.Approved, Illicit
Benzyl alcoholThe risk or severity of adverse effects can be increased when Quetiapine is combined with Benzyl alcohol.Approved
BepridilThe serum concentration of Quetiapine can be increased when it is combined with Bepridil.Approved, Withdrawn
BetaxololThe risk or severity of adverse effects can be increased when Betaxolol is combined with Quetiapine.Approved
BexaroteneThe serum concentration of Quetiapine can be decreased when it is combined with Bexarotene.Approved, Investigational
BiperidenThe serum concentration of Quetiapine can be increased when it is combined with Biperiden.Approved
BisoprololThe risk or severity of adverse effects can be increased when Bisoprolol is combined with Quetiapine.Approved
BoceprevirThe serum concentration of Quetiapine can be increased when it is combined with Boceprevir.Approved
BortezomibBortezomib may increase the QTc-prolonging activities of Quetiapine.Approved, Investigational
BosentanThe serum concentration of Quetiapine can be decreased when it is combined with Bosentan.Approved, Investigational
BosutinibThe serum concentration of Quetiapine can be increased when it is combined with Bosutinib.Approved
BretyliumThe risk or severity of adverse effects can be increased when Bretylium is combined with Quetiapine.Approved
BrexpiprazoleThe risk or severity of adverse effects can be increased when Quetiapine is combined with Brexpiprazole.Approved
BrimonidineThe risk or severity of adverse effects can be increased when Brimonidine is combined with Quetiapine.Approved
BrimonidineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Quetiapine.Approved
BromazepamThe risk or severity of adverse effects can be increased when Quetiapine is combined with Bromazepam.Approved, Illicit
BromocriptineThe therapeutic efficacy of Bromocriptine can be decreased when used in combination with Quetiapine.Approved, Investigational
BrompheniramineThe risk or severity of adverse effects can be increased when Quetiapine is combined with Brompheniramine.Approved
BrotizolamThe risk or severity of adverse effects can be increased when Quetiapine is combined with Brotizolam.Approved, Withdrawn
BuforminThe therapeutic efficacy of Buformin can be decreased when used in combination with Quetiapine.Withdrawn
BumetanideThe risk or severity of adverse effects can be increased when Bumetanide is combined with Quetiapine.Approved
BupivacaineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Quetiapine.Approved, Investigational
BuprenorphineQuetiapine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Approved, Illicit, Investigational, Vet Approved
BupropionThe metabolism of Quetiapine can be decreased when combined with Bupropion.Approved
BuserelinBuserelin may increase the QTc-prolonging activities of Quetiapine.Approved
BuspironeThe serum concentration of Quetiapine can be increased when it is combined with Buspirone.Approved, Investigational
ButabarbitalThe risk or severity of adverse effects can be increased when Butabarbital is combined with Quetiapine.Approved, Illicit
ButacaineThe risk or severity of adverse effects can be increased when Quetiapine is combined with Butacaine.Vet Approved
ButalbitalThe risk or severity of adverse effects can be increased when Quetiapine is combined with Butalbital.Approved, Illicit
ButambenThe risk or severity of adverse effects can be increased when Quetiapine is combined with Butamben.Approved
ButethalThe risk or severity of adverse effects can be increased when Quetiapine is combined with Butethal.Approved, Illicit
ButorphanolThe risk or severity of adverse effects can be increased when Butorphanol is combined with Quetiapine.Approved, Illicit, Vet Approved
CabazitaxelThe serum concentration of Quetiapine can be increased when it is combined with Cabazitaxel.Approved
CabergolineThe risk or severity of adverse effects can be increased when Cabergoline is combined with Quetiapine.Approved
CaffeineThe serum concentration of Quetiapine can be increased when it is combined with Caffeine.Approved
CanagliflozinThe risk or severity of adverse effects can be increased when Quetiapine is combined with Canagliflozin.Approved
CandesartanThe risk or severity of adverse effects can be increased when Candesartan is combined with Quetiapine.Approved
CaptoprilThe risk or severity of adverse effects can be increased when Captopril is combined with Quetiapine.Approved
CarbamazepineThe serum concentration of the active metabolites of Carbamazepine can be increased when Carbamazepine is used in combination with Quetiapine.Approved, Investigational
CarbetocinThe risk or severity of adverse effects can be increased when Quetiapine is combined with Carbetocin.Approved
CarbinoxamineThe risk or severity of adverse effects can be increased when Quetiapine is combined with Carbinoxamine.Approved
CarfentanilThe risk or severity of adverse effects can be increased when Quetiapine is combined with Carfentanil.Illicit, Vet Approved
CarisoprodolThe risk or severity of adverse effects can be increased when Quetiapine is combined with Carisoprodol.Approved
CarteololThe risk or severity of adverse effects can be increased when Carteolol is combined with Quetiapine.Approved
CarvedilolThe risk or severity of adverse effects can be increased when Carvedilol is combined with Quetiapine.Approved, Investigational
CaspofunginThe serum concentration of Quetiapine can be increased when it is combined with Caspofungin.Approved
CastanospermineThe therapeutic efficacy of Castanospermine can be decreased when used in combination with Quetiapine.Experimental
CelecoxibThe metabolism of Quetiapine can be decreased when combined with Celecoxib.Approved, Investigational
CeritinibThe serum concentration of Quetiapine can be increased when it is combined with Ceritinib.Approved
CetirizineThe risk or severity of adverse effects can be increased when Quetiapine is combined with Cetirizine.Approved
Chloral hydrateThe risk or severity of adverse effects can be increased when Quetiapine is combined with Chloral hydrate.Approved, Illicit, Vet Approved
ChloramphenicolThe metabolism of Quetiapine can be decreased when combined with Chloramphenicol.Approved, Vet Approved
ChlordiazepoxideThe risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Quetiapine.Approved, Illicit
ChlormezanoneThe risk or severity of adverse effects can be increased when Chlormezanone is combined with Quetiapine.Approved, Withdrawn
ChloroprocaineThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Quetiapine.Approved
ChloroquineChloroquine may increase the QTc-prolonging activities of Quetiapine.Approved, Vet Approved
ChlorothiazideThe risk or severity of adverse effects can be increased when Chlorothiazide is combined with Quetiapine.Approved, Vet Approved
ChlorphenamineThe risk or severity of adverse effects can be increased when Quetiapine is combined with Chlorphenamine.Approved
ChlorphentermineQuetiapine may decrease the stimulatory activities of Chlorphentermine.Illicit, Withdrawn
ChlorpromazineChlorpromazine may increase the QTc-prolonging activities of Quetiapine.Approved, Vet Approved
ChlorpropamideThe serum concentration of Quetiapine can be increased when it is combined with Chlorpropamide.Approved
ChlorprothixeneThe serum concentration of Quetiapine can be increased when it is combined with Chlorprothixene.Approved, Withdrawn
ChlorthalidoneThe risk or severity of adverse effects can be increased when Chlorthalidone is combined with Quetiapine.Approved
ChlorzoxazoneThe risk or severity of adverse effects can be increased when Quetiapine is combined with Chlorzoxazone.Approved
CholecalciferolThe metabolism of Quetiapine can be decreased when combined with Cholecalciferol.Approved, Nutraceutical
CholesterolThe serum concentration of Quetiapine can be increased when it is combined with Cholesterol.Experimental
Cholic AcidThe serum concentration of Quetiapine can be decreased when it is combined with Cholic Acid.Approved
CiglitazoneThe therapeutic efficacy of Ciglitazone can be decreased when used in combination with Quetiapine.Experimental
CilazaprilThe risk or severity of adverse effects can be increased when Quetiapine is combined with Cilazapril.Approved
CilnidipineThe risk or severity of adverse effects can be increased when Quetiapine is combined with Cilnidipine.Approved
CimetidineThe serum concentration of Quetiapine can be decreased when it is combined with Cimetidine.Approved
CinacalcetThe metabolism of Quetiapine can be decreased when combined with Cinacalcet.Approved
CinchocaineThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Quetiapine.Approved, Vet Approved
CiprofloxacinCiprofloxacin may increase the QTc-prolonging activities of Quetiapine.Approved, Investigational
CisaprideCisapride may increase the QTc-prolonging activities of Quetiapine.Approved, Investigational, Withdrawn
CitalopramCitalopram may increase the QTc-prolonging activities of Quetiapine.Approved
ClarithromycinThe serum concentration of Quetiapine can be increased when it is combined with Clarithromycin.Approved
ClemastineThe metabolism of Quetiapine can be decreased when combined with Clemastine.Approved
ClevidipineThe risk or severity of adverse effects can be increased when Quetiapine is combined with Clevidipine.Approved
ClidiniumThe risk or severity of adverse effects can be increased when Quetiapine is combined with Clidinium.Approved
ClobazamThe metabolism of Quetiapine can be decreased when combined with Clobazam.Approved, Illicit
ClofarabineThe risk or severity of adverse effects can be increased when Quetiapine is combined with Clofarabine.Approved, Investigational
ClofazimineThe serum concentration of Quetiapine can be increased when it is combined with Clofazimine.Approved, Investigational
clomethiazoleThe risk or severity of adverse effects can be increased when Quetiapine is combined with clomethiazole.Investigational
ClomipramineClomipramine may increase the QTc-prolonging activities of Quetiapine.Approved, Vet Approved
ClonazepamThe risk or severity of adverse effects can be increased when Quetiapine is combined with Clonazepam.Approved, Illicit
ClonidineThe risk or severity of adverse effects can be increased when Clonidine is combined with Quetiapine.Approved
ClorazepateThe risk or severity of adverse effects can be increased when Clorazepate is combined with Quetiapine.Approved, Illicit
ClotrimazoleThe metabolism of Quetiapine can be decreased when combined with Clotrimazole.Approved, Vet Approved
ClozapineClozapine may increase the QTc-prolonging activities of Quetiapine.Approved
CobicistatThe serum concentration of Quetiapine can be increased when it is combined with Cobicistat.Approved
CocaineThe metabolism of Quetiapine can be decreased when combined with Cocaine.Approved, Illicit
CodeineThe risk or severity of adverse effects can be increased when Codeine is combined with Quetiapine.Approved, Illicit
ColchicineThe serum concentration of Quetiapine can be increased when it is combined with Colchicine.Approved
ColforsinThe serum concentration of Quetiapine can be increased when it is combined with Colforsin.Experimental
ConivaptanThe serum concentration of Quetiapine can be increased when it is combined with Conivaptan.Approved, Investigational
CrizotinibCrizotinib may increase the QTc-prolonging activities of Quetiapine.Approved
CyclizineThe risk or severity of adverse effects can be increased when Quetiapine is combined with Cyclizine.Approved
CyclobenzaprineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Quetiapine.Approved
CyclophosphamideThe serum concentration of Quetiapine can be increased when it is combined with Cyclophosphamide.Approved, Investigational
CyclosporineThe metabolism of Quetiapine can be decreased when combined with Cyclosporine.Approved, Investigational, Vet Approved
CyproheptadineThe risk or severity of adverse effects can be increased when Quetiapine is combined with Cyproheptadine.Approved
DabrafenibThe serum concentration of Quetiapine can be decreased when it is combined with Dabrafenib.Approved
DaclatasvirThe serum concentration of Quetiapine can be increased when it is combined with Daclatasvir.Approved
DactinomycinThe serum concentration of Quetiapine can be increased when it is combined with Dactinomycin.Approved
DantroleneThe risk or severity of adverse effects can be increased when Quetiapine is combined with Dantrolene.Approved
DapagliflozinThe risk or severity of adverse effects can be increased when Quetiapine is combined with Dapagliflozin.Approved
DapiprazoleThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Quetiapine.Approved
DapoxetineThe risk or severity of adverse effects can be increased when Quetiapine is combined with Dapoxetine.Investigational
DarifenacinThe metabolism of Quetiapine can be decreased when combined with Darifenacin.Approved, Investigational
DarunavirThe serum concentration of Quetiapine can be increased when it is combined with Darunavir.Approved
DasatinibThe serum concentration of Quetiapine can be increased when it is combined with Dasatinib.Approved, Investigational
DaunorubicinThe serum concentration of Quetiapine can be decreased when it is combined with Daunorubicin.Approved
DeferasiroxThe serum concentration of Quetiapine can be decreased when it is combined with Deferasirox.Approved, Investigational
DegarelixDegarelix may increase the QTc-prolonging activities of Quetiapine.Approved
DelavirdineThe metabolism of Quetiapine can be decreased when combined with Delavirdine.Approved
DeoxyspergualinThe therapeutic efficacy of Deoxyspergualin can be decreased when used in combination with Quetiapine.Investigational
deramciclaneThe risk or severity of adverse effects can be increased when Quetiapine is combined with deramciclane.Investigational
DesfluraneDesflurane may increase the QTc-prolonging activities of Quetiapine.Approved
DesipramineDesipramine may increase the QTc-prolonging activities of Quetiapine.Approved
DesloratadineThe serum concentration of Quetiapine can be increased when it is combined with Desloratadine.Approved, Investigational
DesvenlafaxineThe risk or severity of adverse effects can be increased when Desvenlafaxine is combined with Quetiapine.Approved
DetomidineThe risk or severity of adverse effects can be increased when Quetiapine is combined with Detomidine.Vet Approved
DexamethasoneThe serum concentration of Quetiapine can be decreased when it is combined with Dexamethasone.Approved, Investigational, Vet Approved
DexbrompheniramineThe risk or severity of adverse effects can be increased when Quetiapine is combined with Dexbrompheniramine.Approved
DexmedetomidineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Quetiapine.Approved, Vet Approved
DextroamphetamineQuetiapine may decrease the stimulatory activities of Dextroamphetamine.Approved, Illicit
DextromethorphanThe serum concentration of Quetiapine can be increased when it is combined with Dextromethorphan.Approved
DextromoramideThe risk or severity of adverse effects can be increased when Quetiapine is combined with Dextromoramide.Experimental, Illicit
DextropropoxypheneThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Quetiapine.Approved, Illicit, Withdrawn
DezocineThe risk or severity of adverse effects can be increased when Dezocine is combined with Quetiapine.Approved
DiazepamThe risk or severity of adverse effects can be increased when Diazepam is combined with Quetiapine.Approved, Illicit, Vet Approved
DiclofenacThe serum concentration of Quetiapine can be increased when it is combined with Diclofenac.Approved, Vet Approved
DiclofenamideThe risk or severity of adverse effects can be increased when Diclofenamide is combined with Quetiapine.Approved
DiethylpropionQuetiapine may decrease the stimulatory activities of Diethylpropion.Approved, Illicit
DifenoxinThe risk or severity of adverse effects can be increased when Quetiapine is combined with Difenoxin.Approved, Illicit
DigoxinThe serum concentration of Quetiapine can be decreased when it is combined with Digoxin.Approved
DihydrocodeineThe risk or severity of adverse effects can be increased when Quetiapine is combined with Dihydrocodeine.Approved, Illicit
DihydroergotamineThe metabolism of Quetiapine can be decreased when combined with Dihydroergotamine.Approved
DihydroetorphineThe risk or severity of adverse effects can be increased when Quetiapine is combined with Dihydroetorphine.Experimental, Illicit
DihydromorphineThe risk or severity of adverse effects can be increased when Quetiapine is combined with Dihydromorphine.Experimental, Illicit
DiltiazemThe risk or severity of adverse effects can be increased when Diltiazem is combined with Quetiapine.Approved
DimenhydrinateThe risk or severity of adverse effects can be increased when Quetiapine is combined with Dimenhydrinate.Approved
DinutuximabThe risk or severity of adverse effects can be increased when Quetiapine is combined with Dinutuximab.Approved
DiphenhydramineDiphenhydramine may increase the QTc-prolonging activities of Quetiapine.Approved
DiphenoxylateThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Quetiapine.Approved, Illicit
DipyridamoleThe risk or severity of adverse effects can be increased when Dipyridamole is combined with Quetiapine.Approved
DisopyramideDisopyramide may increase the QTc-prolonging activities of Quetiapine.Approved
DofetilideDofetilide may increase the QTc-prolonging activities of Quetiapine.Approved
DolasetronDolasetron may increase the QTc-prolonging activities of Quetiapine.Approved
DomperidoneDomperidone may increase the QTc-prolonging activities of Quetiapine.Approved, Investigational, Vet Approved
DoramectinThe risk or severity of adverse effects can be increased when Quetiapine is combined with Doramectin.Vet Approved
DoxazosinThe risk or severity of adverse effects can be increased when Doxazosin is combined with Quetiapine.Approved
DoxepinDoxepin may increase the QTc-prolonging activities of Quetiapine.Approved
DoxorubicinThe serum concentration of Quetiapine can be decreased when it is combined with Doxorubicin.Approved, Investigational
DoxycyclineThe metabolism of Quetiapine can be decreased when combined with Doxycycline.Approved, Investigational, Vet Approved
DoxylamineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Quetiapine.Approved, Vet Approved
DPDPEThe risk or severity of adverse effects can be increased when Quetiapine is combined with DPDPE.Investigational
DronabinolDronabinol may increase the central nervous system depressant (CNS depressant) activities of Quetiapine.Approved, Illicit
DronedaroneQuetiapine may increase the QTc-prolonging activities of Dronedarone.Approved
DroperidolDroperidol may increase the central nervous system depressant (CNS depressant) activities of Quetiapine.Approved, Vet Approved
DrotebanolThe risk or severity of adverse effects can be increased when Quetiapine is combined with Drotebanol.Experimental, Illicit
DulaglutideThe therapeutic efficacy of Dulaglutide can be decreased when used in combination with Quetiapine.Approved
DuloxetineQuetiapine may increase the orthostatic hypotensive activities of Duloxetine.Approved
DyclonineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Quetiapine.Approved
EcgonineThe risk or severity of adverse effects can be increased when Quetiapine is combined with Ecgonine.Experimental, Illicit
ECGONINE METHYL ESTERThe risk or severity of adverse effects can be increased when Quetiapine is combined with ECGONINE METHYL ESTER.Experimental
EcopipamThe risk or severity of adverse effects can be increased when Quetiapine is combined with Ecopipam.Investigational
EfavirenzThe serum concentration of Quetiapine can be decreased when it is combined with Efavirenz.Approved, Investigational
EfonidipineThe risk or severity of adverse effects can be increased when Quetiapine is combined with Efonidipine.Approved
ElbasvirThe serum concentration of Quetiapine can be increased when it is combined with Elbasvir.Approved
EletriptanThe risk or severity of adverse effects can be increased when Eletriptan is combined with Quetiapine.Approved, Investigational
EliglustatQuetiapine may increase the QTc-prolonging activities of Eliglustat.Approved
EmpagliflozinThe risk or severity of adverse effects can be increased when Quetiapine is combined with Empagliflozin.Approved
EnalaprilThe risk or severity of adverse effects can be increased when Enalapril is combined with Quetiapine.Approved, Vet Approved
EnalaprilatThe risk or severity of adverse effects can be increased when Quetiapine is combined with Enalaprilat.Approved
EnfluraneThe risk or severity of adverse effects can be increased when Enflurane is combined with Quetiapine.Approved, Vet Approved
EntacaponeThe risk or severity of adverse effects can be increased when Quetiapine is combined with Entacapone.Approved, Investigational
EnzalutamideThe serum concentration of Quetiapine can be decreased when it is combined with Enzalutamide.Approved
EplerenoneThe risk or severity of adverse effects can be increased when Eplerenone is combined with Quetiapine.Approved
EpoprostenolThe risk or severity of adverse effects can be increased when Quetiapine is combined with Epoprostenol.Approved
EprosartanThe risk or severity of adverse effects can be increased when Eprosartan is combined with Quetiapine.Approved
Ergoloid mesylateThe risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Quetiapine.Approved
ErgonovineThe serum concentration of Quetiapine can be increased when it is combined with Ergonovine.Approved
ErgotamineThe serum concentration of Quetiapine can be increased when it is combined with Ergotamine.Approved
EribulinEribulin may increase the QTc-prolonging activities of Quetiapine.Approved, Investigational
ErythromycinErythromycin may increase the QTc-prolonging activities of Quetiapine.Approved, Vet Approved
EscitalopramEscitalopram may increase the QTc-prolonging activities of Quetiapine.Approved, Investigational
Eslicarbazepine acetateThe serum concentration of Quetiapine can be decreased when it is combined with Eslicarbazepine acetate.Approved
EsmololThe risk or severity of adverse effects can be increased when Esmolol is combined with Quetiapine.Approved
EsomeprazoleThe metabolism of Quetiapine can be decreased when combined with Esomeprazole.Approved, Investigational
EstazolamThe risk or severity of adverse effects can be increased when Estazolam is combined with Quetiapine.Approved, Illicit
EstramustineThe serum concentration of Quetiapine can be increased when it is combined with Estramustine.Approved
EstriolThe serum concentration of Quetiapine can be decreased when it is combined with Estriol.Approved, Vet Approved
EstroneThe serum concentration of Quetiapine can be decreased when it is combined with Estrone.Approved
EszopicloneThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Quetiapine.Approved
Etacrynic acidThe risk or severity of adverse effects can be increased when Etacrynic acid is combined with Quetiapine.Approved
EthanolQuetiapine may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Approved
EthchlorvynolThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Quetiapine.Approved, Illicit, Withdrawn
EthosuximideThe risk or severity of adverse effects can be increased when Quetiapine is combined with Ethosuximide.Approved
EthotoinThe risk or severity of adverse effects can be increased when Quetiapine is combined with Ethotoin.Approved
Ethyl carbamateThe risk or severity of adverse effects can be increased when Quetiapine is combined with Ethyl carbamate.Withdrawn
Ethyl loflazepateThe risk or severity of adverse effects can be increased when Quetiapine is combined with Ethyl loflazepate.Approved, Illicit
EthylmorphineThe risk or severity of adverse effects can be increased when Quetiapine is combined with Ethylmorphine.Approved, Illicit
EtidocaineThe risk or severity of adverse effects can be increased when Quetiapine is combined with Etidocaine.Approved
EtifoxineThe risk or severity of adverse effects can be increased when Quetiapine is combined with Etifoxine.Withdrawn
EtizolamThe risk or severity of adverse effects can be increased when Quetiapine is combined with Etizolam.Approved
EtomidateThe risk or severity of adverse effects can be increased when Etomidate is combined with Quetiapine.Approved
EtoperidoneThe risk or severity of adverse effects can be increased when Quetiapine is combined with Etoperidone.Approved
EtoposideThe serum concentration of Quetiapine can be increased when it is combined with Etoposide.Approved
EtorphineThe risk or severity of adverse effects can be increased when Quetiapine is combined with Etorphine.Illicit, Vet Approved
EtravirineThe serum concentration of Quetiapine can be decreased when it is combined with Etravirine.Approved
ExenatideThe therapeutic efficacy of Exenatide can be decreased when used in combination with Quetiapine.Approved, Investigational
EzogabineEzogabine may increase the QTc-prolonging activities of Quetiapine.Approved
FamotidineFamotidine may increase the QTc-prolonging activities of Quetiapine.Approved
FelbamateFelbamate may increase the QTc-prolonging activities of Quetiapine.Approved
FelodipineThe risk or severity of adverse effects can be increased when Felodipine is combined with Quetiapine.Approved, Investigational
FencamfamineThe risk or severity of adverse effects can be increased when Quetiapine is combined with Fencamfamine.Approved, Illicit, Withdrawn
FenoldopamThe risk or severity of adverse effects can be increased when Quetiapine is combined with Fenoldopam.Approved
FentanylThe serum concentration of Quetiapine can be increased when it is combined with Fentanyl.Approved, Illicit, Investigational, Vet Approved
FesoterodineThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Quetiapine.Approved
FexofenadineThe serum concentration of Quetiapine can be increased when it is combined with Fexofenadine.Approved
FidaxomicinThe serum concentration of Quetiapine can be increased when it is combined with Fidaxomicin.Approved
FimasartanThe risk or severity of adverse effects can be increased when Quetiapine is combined with Fimasartan.Approved
FingolimodFingolimod may increase the QTc-prolonging activities of Quetiapine.Approved, Investigational
FlecainideFlecainide may increase the QTc-prolonging activities of Quetiapine.Approved, Withdrawn
FlibanserinThe risk or severity of adverse effects can be increased when Quetiapine is combined with Flibanserin.Approved
FluconazoleFluconazole may increase the QTc-prolonging activities of Quetiapine.Approved
FludiazepamThe risk or severity of adverse effects can be increased when Quetiapine is combined with Fludiazepam.Approved, Illicit
FlunarizineThe risk or severity of adverse effects can be increased when Quetiapine is combined with Flunarizine.Approved
FlunitrazepamThe risk or severity of adverse effects can be increased when Quetiapine is combined with Flunitrazepam.Approved, Illicit
FluoxetineFluoxetine may increase the QTc-prolonging activities of Quetiapine.Approved, Vet Approved
FlupentixolFlupentixol may increase the QTc-prolonging activities of Quetiapine.Approved, Withdrawn
FluphenazineThe serum concentration of Quetiapine can be increased when it is combined with Fluphenazine.Approved
FlurazepamThe serum concentration of Quetiapine can be increased when it is combined with Flurazepam.Approved, Illicit
FluspirileneThe risk or severity of adverse effects can be increased when Quetiapine is combined with Fluspirilene.Approved
Fluticasone PropionateThe risk or severity of adverse effects can be increased when Quetiapine is combined with Fluticasone Propionate.Approved
FluvoxamineThe metabolism of Quetiapine can be decreased when combined with Fluvoxamine.Approved, Investigational
FormoterolFormoterol may increase the QTc-prolonging activities of Quetiapine.Approved, Investigational
FosamprenavirThe metabolism of Quetiapine can be decreased when combined with Fosamprenavir.Approved
FosaprepitantThe serum concentration of Quetiapine can be increased when it is combined with Fosaprepitant.Approved
FoscarnetFoscarnet may increase the QTc-prolonging activities of Quetiapine.Approved
FosinoprilThe risk or severity of adverse effects can be increased when Fosinopril is combined with Quetiapine.Approved
FosphenytoinThe serum concentration of Quetiapine can be decreased when it is combined with Fosphenytoin.Approved
FospropofolThe risk or severity of adverse effects can be increased when Quetiapine is combined with Fospropofol.Approved, Illicit
FrovatriptanThe risk or severity of adverse effects can be increased when Frovatriptan is combined with Quetiapine.Approved, Investigational
FurosemideThe risk or severity of adverse effects can be increased when Furosemide is combined with Quetiapine.Approved, Vet Approved
Fusidic AcidThe serum concentration of Quetiapine can be increased when it is combined with Fusidic Acid.Approved
GabapentinThe risk or severity of adverse effects can be increased when Gabapentin is combined with Quetiapine.Approved, Investigational
gabapentin enacarbilThe risk or severity of adverse effects can be increased when Quetiapine is combined with gabapentin enacarbil.Approved
Gadobenic acidGadobenic acid may increase the QTc-prolonging activities of Quetiapine.Approved
GalantamineGalantamine may increase the QTc-prolonging activities of Quetiapine.Approved
Gamma Hydroxybutyric AcidThe risk or severity of adverse effects can be increased when Quetiapine is combined with Gamma Hydroxybutyric Acid.Approved, Illicit
GefitinibThe serum concentration of Quetiapine can be increased when it is combined with Gefitinib.Approved, Investigational
GemfibrozilThe metabolism of Quetiapine can be decreased when combined with Gemfibrozil.Approved
GemifloxacinGemifloxacin may increase the QTc-prolonging activities of Quetiapine.Approved, Investigational
GenisteinThe serum concentration of Quetiapine can be increased when it is combined with Genistein.Investigational
GepironeThe risk or severity of adverse effects can be increased when Quetiapine is combined with Gepirone.Investigational
GlibornurideThe therapeutic efficacy of Glibornuride can be decreased when used in combination with Quetiapine.Withdrawn
GliclazideThe therapeutic efficacy of Gliclazide can be decreased when used in combination with Quetiapine.Approved
GlimepirideThe therapeutic efficacy of Glimepiride can be decreased when used in combination with Quetiapine.Approved
GlipizideThe therapeutic efficacy of Glipizide can be decreased when used in combination with Quetiapine.Approved
GliquidoneThe therapeutic efficacy of Gliquidone can be decreased when used in combination with Quetiapine.Approved
GlutethimideThe risk or severity of adverse effects can be increased when Quetiapine is combined with Glutethimide.Approved, Illicit
GlyburideThe serum concentration of Quetiapine can be increased when it is combined with Glyburide.Approved
GlycerolThe serum concentration of Quetiapine can be increased when it is combined with Glycerol.Experimental
GoserelinGoserelin may increase the QTc-prolonging activities of Quetiapine.Approved
Gramicidin DThe serum concentration of Quetiapine can be increased when it is combined with Gramicidin D.Approved
GranisetronGranisetron may increase the QTc-prolonging activities of Quetiapine.Approved, Investigational
GrepafloxacinThe serum concentration of Quetiapine can be increased when it is combined with Grepafloxacin.Withdrawn
GuanfacineThe risk or severity of adverse effects can be increased when Guanfacine is combined with Quetiapine.Approved, Investigational
GusperimusThe therapeutic efficacy of Gusperimus can be decreased when used in combination with Quetiapine.Investigational
HalazepamThe risk or severity of adverse effects can be increased when Halazepam is combined with Quetiapine.Approved, Illicit, Withdrawn
HaloperidolHaloperidol may increase the QTc-prolonging activities of Quetiapine.Approved
HalothaneThe risk or severity of adverse effects can be increased when Halothane is combined with Quetiapine.Approved, Vet Approved
HeroinThe risk or severity of adverse effects can be increased when Quetiapine is combined with Heroin.Approved, Illicit
HexobarbitalThe risk or severity of adverse effects can be increased when Quetiapine is combined with Hexobarbital.Approved
HistrelinHistrelin may increase the QTc-prolonging activities of Quetiapine.Approved
HydralazineThe risk or severity of adverse effects can be increased when Quetiapine is combined with Hydralazine.Approved
HydrochlorothiazideThe risk or severity of adverse effects can be increased when Hydrochlorothiazide is combined with Quetiapine.Approved, Vet Approved
HydrocodoneQuetiapine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Illicit
HydrocortisoneThe serum concentration of Quetiapine can be increased when it is combined with Hydrocortisone.Approved, Vet Approved
HydroflumethiazideThe risk or severity of adverse effects can be increased when Quetiapine is combined with Hydroflumethiazide.Approved
HydromorphoneThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Quetiapine.Approved, Illicit
Hydroxyamphetamine hydrobromideQuetiapine may decrease the stimulatory activities of Hydroxyamphetamine hydrobromide.Approved
HydroxyzineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Quetiapine.Approved
IbandronateIbandronate may increase the QTc-prolonging activities of Quetiapine.Approved, Investigational
IbutilideIbutilide may increase the QTc-prolonging activities of Quetiapine.Approved
IdelalisibThe serum concentration of Quetiapine can be increased when it is combined with Idelalisib.Approved
IloperidoneQuetiapine may increase the QTc-prolonging activities of Iloperidone.Approved
IloprostThe risk or severity of adverse effects can be increased when Quetiapine is combined with Iloprost.Approved, Investigational
ImatinibThe metabolism of Quetiapine can be decreased when combined with Imatinib.Approved
ImidaprilThe risk or severity of adverse effects can be increased when Quetiapine is combined with Imidapril.Investigational
ImipramineImipramine may increase the QTc-prolonging activities of Quetiapine.Approved
IndacaterolIndacaterol may increase the QTc-prolonging activities of Quetiapine.Approved
IndalpineThe risk or severity of adverse effects can be increased when Quetiapine is combined with Indalpine.Investigational, Withdrawn
IndapamideIndapamide may increase the QTc-prolonging activities of Quetiapine.Approved
IndinavirThe serum concentration of Quetiapine can be increased when it is combined with Indinavir.Approved
IndomethacinThe serum concentration of Quetiapine can be increased when it is combined with Indomethacin.Approved, Investigational
IndoraminThe risk or severity of adverse effects can be increased when Quetiapine is combined with Indoramin.Withdrawn
Insulin AspartThe therapeutic efficacy of Insulin Aspart can be decreased when used in combination with Quetiapine.Approved
Insulin DetemirThe therapeutic efficacy of Insulin Detemir can be decreased when used in combination with Quetiapine.Approved
Insulin GlargineThe therapeutic efficacy of Insulin Glargine can be decreased when used in combination with Quetiapine.Approved
Insulin GlulisineThe therapeutic efficacy of Insulin Glulisine can be decreased when used in combination with Quetiapine.Approved
Insulin LisproThe therapeutic efficacy of Insulin Lispro can be decreased when used in combination with Quetiapine.Approved
Insulin PorkThe therapeutic efficacy of Insulin Pork can be decreased when used in combination with Quetiapine.Approved
IrbesartanThe risk or severity of adverse effects can be increased when Irbesartan is combined with Quetiapine.Approved, Investigational
IsavuconazoniumThe metabolism of Quetiapine can be decreased when combined with Isavuconazonium.Approved, Investigational
IsocarboxazidThe risk or severity of adverse effects can be increased when Isocarboxazid is combined with Quetiapine.Approved
IsofluraneIsoflurane may increase the QTc-prolonging activities of Quetiapine.Approved, Vet Approved
IsoniazidThe metabolism of Quetiapine can be decreased when combined with Isoniazid.Approved
Isosorbide DinitrateThe risk or severity of adverse effects can be increased when Isosorbide Dinitrate is combined with Quetiapine.Approved
Isosorbide MononitrateThe risk or severity of adverse effects can be increased when Isosorbide Mononitrate is combined with Quetiapine.Approved
IsoxsuprineThe risk or severity of adverse effects can be increased when Quetiapine is combined with Isoxsuprine.Approved, Withdrawn
IsradipineIsradipine may increase the QTc-prolonging activities of Quetiapine.Approved
ItraconazoleThe serum concentration of Quetiapine can be increased when it is combined with Itraconazole.Approved, Investigational
IvabradineIvabradine may increase the QTc-prolonging activities of Quetiapine.Approved
IvacaftorThe serum concentration of Quetiapine can be increased when it is combined with Ivacaftor.Approved
IvermectinThe serum concentration of Quetiapine can be increased when it is combined with Ivermectin.Approved, Vet Approved
KetamineThe serum concentration of Quetiapine can be increased when it is combined with Ketamine.Approved, Vet Approved
KetazolamThe risk or severity of adverse effects can be increased when Quetiapine is combined with Ketazolam.Approved
KetobemidoneThe risk or severity of adverse effects can be increased when Quetiapine is combined with Ketobemidone.Approved
KetoconazoleThe serum concentration of Quetiapine can be increased when it is combined with Ketoconazole.Approved, Investigational
LabetalolThe risk or severity of adverse effects can be increased when Labetalol is combined with Quetiapine.Approved
LacidipineThe risk or severity of adverse effects can be increased when Quetiapine is combined with Lacidipine.Approved
LamotrigineThe risk or severity of adverse effects can be increased when Quetiapine is combined with Lamotrigine.Approved, Investigational
LansoprazoleThe serum concentration of Quetiapine can be increased when it is combined with Lansoprazole.Approved, Investigational
LapatinibLapatinib may increase the QTc-prolonging activities of Quetiapine.Approved, Investigational
LenvatinibLenvatinib may increase the QTc-prolonging activities of Quetiapine.Approved
LercanidipineThe risk or severity of adverse effects can be increased when Quetiapine is combined with Lercanidipine.Approved, Investigational
LeuprolideLeuprolide may increase the QTc-prolonging activities of Quetiapine.Approved, Investigational
LevetiracetamThe risk or severity of adverse effects can be increased when Quetiapine is combined with Levetiracetam.Approved, Investigational
LevobunololThe risk or severity of adverse effects can be increased when Levobunolol is combined with Quetiapine.Approved
LevobupivacaineThe risk or severity of adverse effects can be increased when Levobupivacaine is combined with Quetiapine.Approved
LevocabastineThe risk or severity of adverse effects can be increased when Quetiapine is combined with Levocabastine.Approved
LevocetirizineThe risk or severity of adverse effects can be increased when Quetiapine is combined with Levocetirizine.Approved
LevodopaQuetiapine may increase the orthostatic hypotensive activities of Levodopa.Approved
LevofloxacinLevofloxacin may increase the QTc-prolonging activities of Quetiapine.Approved, Investigational
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Quetiapine is combined with Levomethadyl Acetate.Approved
LevomilnacipranThe risk or severity of adverse effects can be increased when Levomilnacipran is combined with Quetiapine.Approved
LevorphanolThe risk or severity of adverse effects can be increased when Levorphanol is combined with Quetiapine.Approved
LevosimendanThe risk or severity of adverse effects can be increased when Quetiapine is combined with Levosimendan.Approved, Investigational
LevothyroxineThe serum concentration of Quetiapine can be decreased when it is combined with Levothyroxine.Approved
LidocaineThe serum concentration of Quetiapine can be increased when it is combined with Lidocaine.Approved, Vet Approved
LinagliptinThe therapeutic efficacy of Linagliptin can be decreased when used in combination with Quetiapine.Approved
LinezolidThe risk or severity of adverse effects can be increased when Linezolid is combined with Quetiapine.Approved, Investigational
LiothyronineThe serum concentration of Quetiapine can be decreased when it is combined with Liothyronine.Approved, Vet Approved
LiotrixThe serum concentration of Quetiapine can be decreased when it is combined with Liotrix.Approved
LiraglutideThe therapeutic efficacy of Liraglutide can be decreased when used in combination with Quetiapine.Approved
LisdexamfetamineQuetiapine may decrease the stimulatory activities of Lisdexamfetamine.Approved, Investigational
LisinoprilThe risk or severity of adverse effects can be increased when Lisinopril is combined with Quetiapine.Approved, Investigational
LithiumLithium may increase the neurotoxic activities of Quetiapine.Approved
LofentanilThe risk or severity of adverse effects can be increased when Quetiapine is combined with Lofentanil.Illicit
LofexidineThe risk or severity of adverse effects can be increased when Quetiapine is combined with Lofexidine.Approved, Investigational
LomitapideThe serum concentration of Quetiapine can be increased when it is combined with Lomitapide.Approved
LoperamideThe serum concentration of Quetiapine can be increased when it is combined with Loperamide.Approved
LopinavirThe serum concentration of Quetiapine can be increased when it is combined with Lopinavir.Approved
LoratadineThe serum concentration of Quetiapine can be increased when it is combined with Loratadine.Approved
LorazepamThe risk or severity of adverse effects can be increased when Lorazepam is combined with Quetiapine.Approved
LorcaserinThe metabolism of Quetiapine can be decreased when combined with Lorcaserin.Approved
LosartanThe risk or severity of adverse effects can be increased when Losartan is combined with Quetiapine.Approved
LovastatinThe metabolism of Quetiapine can be decreased when combined with Lovastatin.Approved, Investigational
LoxapineThe risk or severity of adverse effects can be increased when Loxapine is combined with Quetiapine.Approved
Lu AA21004The risk or severity of adverse effects can be increased when Quetiapine is combined with Lu AA21004.Investigational
LuliconazoleThe serum concentration of Quetiapine can be increased when it is combined with Luliconazole.Approved
LumacaftorThe serum concentration of Quetiapine can be decreased when it is combined with Lumacaftor.Approved
LumefantrineQuetiapine may increase the QTc-prolonging activities of Lumefantrine.Approved
LurasidoneThe risk or severity of adverse effects can be increased when Quetiapine is combined with Lurasidone.Approved
Magnesium SulfateMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Quetiapine.Approved, Vet Approved
MannitolThe risk or severity of adverse effects can be increased when Mannitol is combined with Quetiapine.Approved, Investigational
MaprotilineMaprotiline may increase the QTc-prolonging activities of Quetiapine.Approved
MebendazoleThe serum concentration of Quetiapine can be increased when it is combined with Mebendazole.Approved, Vet Approved
MecamylamineThe risk or severity of adverse effects can be increased when Mecamylamine is combined with Quetiapine.Approved
MeclizineThe risk or severity of adverse effects can be increased when Quetiapine is combined with Meclizine.Approved
MedetomidineThe risk or severity of adverse effects can be increased when Quetiapine is combined with Medetomidine.Vet Approved
MefloquineMefloquine may increase the QTc-prolonging activities of Quetiapine.Approved
Megestrol acetateThe serum concentration of Quetiapine can be increased when it is combined with Megestrol acetate.Approved, Vet Approved
MelatoninThe risk or severity of adverse effects can be increased when Melatonin is combined with Quetiapine.Approved, Nutraceutical, Vet Approved
MelperoneThe risk or severity of adverse effects can be increased when Quetiapine is combined with Melperone.Approved
MephedroneQuetiapine may decrease the stimulatory activities of Mephedrone.Investigational
MephentermineQuetiapine may decrease the stimulatory activities of Mephentermine.Approved
MepivacaineThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Quetiapine.Approved, Vet Approved
MeprobamateThe serum concentration of Quetiapine can be increased when it is combined with Meprobamate.Approved, Illicit
MequitazineQuetiapine may increase the arrhythmogenic activities of Mequitazine.Approved
MesoridazineThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Quetiapine.Approved
MetaxaloneThe risk or severity of adverse effects can be increased when Quetiapine is combined with Metaxalone.Approved
MetforminThe therapeutic efficacy of Metformin can be decreased when used in combination with Quetiapine.Approved
MethadoneMethadone may increase the QTc-prolonging activities of Quetiapine.Approved
Methadyl AcetateThe risk or severity of adverse effects can be increased when Quetiapine is combined with Methadyl Acetate.Approved, Illicit
MethamphetamineQuetiapine may decrease the stimulatory activities of Methamphetamine.Approved, Illicit
MethapyrileneThe risk or severity of adverse effects can be increased when Quetiapine is combined with Methapyrilene.Withdrawn
MethaqualoneThe risk or severity of adverse effects can be increased when Quetiapine is combined with Methaqualone.Illicit, Withdrawn
MethazolamideThe risk or severity of adverse effects can be increased when Methazolamide is combined with Quetiapine.Approved
MethocarbamolThe risk or severity of adverse effects can be increased when Quetiapine is combined with Methocarbamol.Approved, Vet Approved
MethohexitalThe risk or severity of adverse effects can be increased when Methohexital is combined with Quetiapine.Approved
MethotrimeprazineQuetiapine may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved
MethoxyfluraneThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Quetiapine.Approved, Vet Approved
MethsuximideThe risk or severity of adverse effects can be increased when Quetiapine is combined with Methsuximide.Approved
MethyclothiazideThe risk or severity of adverse effects can be increased when Methyclothiazide is combined with Quetiapine.Approved
MethyldopaThe risk or severity of adverse effects can be increased when Methyldopa is combined with Quetiapine.Approved
MethylphenidateThe risk or severity of adverse effects can be increased when Quetiapine is combined with Methylphenidate.Approved, Investigational
MethylphenobarbitalThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Quetiapine.Approved
MetipranololThe risk or severity of adverse effects can be increased when Metipranolol is combined with Quetiapine.Approved
MetoclopramideThe risk or severity of adverse effects can be increased when Metoclopramide is combined with Quetiapine.Approved, Investigational
MetolazoneThe risk or severity of adverse effects can be increased when Metolazone is combined with Quetiapine.Approved
MetoprololThe serum concentration of Metoprolol can be increased when it is combined with Quetiapine.Approved, Investigational
MetronidazoleMetronidazole may increase the QTc-prolonging activities of Quetiapine.Approved
MetyrosineQuetiapine may increase the sedative activities of Metyrosine.Approved
MibefradilThe serum concentration of Quetiapine can be increased when it is combined with Mibefradil.Withdrawn
MiconazoleThe serum concentration of Quetiapine can be increased when it is combined with Miconazole.Approved, Investigational, Vet Approved
MidazolamThe serum concentration of Quetiapine can be decreased when it is combined with Midazolam.Approved, Illicit
MifepristoneMifepristone may increase the QTc-prolonging activities of Quetiapine.Approved, Investigational
MiglitolThe therapeutic efficacy of Miglitol can be decreased when used in combination with Quetiapine.Approved
MiglustatThe therapeutic efficacy of Miglustat can be decreased when used in combination with Quetiapine.Approved
MilnacipranThe risk or severity of adverse effects can be increased when Milnacipran is combined with Quetiapine.Approved
MinocyclineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Quetiapine.Approved, Investigational
MinoxidilThe risk or severity of adverse effects can be increased when Minoxidil is combined with Quetiapine.Approved
MirabegronMirabegron may increase the QTc-prolonging activities of Quetiapine.Approved
MirtazapineQuetiapine may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Approved
MitiglinideThe therapeutic efficacy of Mitiglinide can be decreased when used in combination with Quetiapine.Approved, Investigational
MitomycinThe serum concentration of Quetiapine can be increased when it is combined with Mitomycin.Approved
MitotaneThe serum concentration of Quetiapine can be decreased when it is combined with Mitotane.Approved
MitoxantroneThe serum concentration of Quetiapine can be decreased when it is combined with Mitoxantrone.Approved, Investigational
MMDAQuetiapine may decrease the stimulatory activities of MMDA.Experimental, Illicit
MoclobemideThe metabolism of Quetiapine can be decreased when combined with Moclobemide.Approved
ModafinilThe serum concentration of Quetiapine can be decreased when it is combined with Modafinil.Approved, Investigational
MoexiprilMoexipril may increase the QTc-prolonging activities of Quetiapine.Approved
MolindoneThe risk or severity of adverse effects can be increased when Quetiapine is combined with Molindone.Approved
MorphineThe serum concentration of Quetiapine can be increased when it is combined with Morphine.Approved, Investigational
MoxifloxacinMoxifloxacin may increase the QTc-prolonging activities of Quetiapine.Approved, Investigational
MoxonidineThe risk or severity of adverse effects can be increased when Quetiapine is combined with Moxonidine.Approved
NabiloneNabilone may increase the central nervous system depressant (CNS depressant) activities of Quetiapine.Approved, Investigational
NadololThe risk or severity of adverse effects can be increased when Nadolol is combined with Quetiapine.Approved
NafcillinThe serum concentration of Quetiapine can be decreased when it is combined with Nafcillin.Approved
NalbuphineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Quetiapine.Approved
NaltrexoneThe serum concentration of Quetiapine can be increased when it is combined with Naltrexone.Approved, Investigational, Vet Approved
NaratriptanThe risk or severity of adverse effects can be increased when Naratriptan is combined with Quetiapine.Approved, Investigational
NaringeninThe serum concentration of Quetiapine can be increased when it is combined with Naringenin.Experimental
NateglinideThe therapeutic efficacy of Nateglinide can be decreased when used in combination with Quetiapine.Approved, Investigational
NebivololThe risk or severity of adverse effects can be increased when Quetiapine is combined with Nebivolol.Approved, Investigational
NefazodoneThe serum concentration of Quetiapine can be increased when it is combined with Nefazodone.Approved, Withdrawn
NelfinavirThe serum concentration of Quetiapine can be increased when it is combined with Nelfinavir.Approved
NeostigmineThe serum concentration of Quetiapine can be increased when it is combined with Neostigmine.Approved, Vet Approved
NesiritideThe risk or severity of adverse effects can be increased when Quetiapine is combined with Nesiritide.Approved, Investigational
NetupitantThe serum concentration of Quetiapine can be increased when it is combined with Netupitant.Approved
NevirapineThe serum concentration of Quetiapine can be decreased when it is combined with Nevirapine.Approved
NicardipineNicardipine may increase the QTc-prolonging activities of Quetiapine.Approved
NicorandilNicorandil may increase the hypotensive activities of Quetiapine.Approved
NifedipineThe risk or severity of adverse effects can be increased when Nifedipine is combined with Quetiapine.Approved
NilotinibQuetiapine may increase the QTc-prolonging activities of Nilotinib.Approved, Investigational
NilvadipineThe risk or severity of adverse effects can be increased when Quetiapine is combined with Nilvadipine.Approved
NimodipineThe risk or severity of adverse effects can be increased when Nimodipine is combined with Quetiapine.Approved
NisoldipineThe risk or severity of adverse effects can be increased when Nisoldipine is combined with Quetiapine.Approved
NitrazepamThe serum concentration of Quetiapine can be increased when it is combined with Nitrazepam.Approved
NitrendipineThe serum concentration of Quetiapine can be increased when it is combined with Nitrendipine.Approved
Nitric OxideThe risk or severity of adverse effects can be increased when Quetiapine is combined with Nitric Oxide.Approved
NitroglycerinThe risk or severity of adverse effects can be increased when Nitroglycerin is combined with Quetiapine.Approved, Investigational
NitroprussideThe risk or severity of adverse effects can be increased when Nitroprusside is combined with Quetiapine.Approved
Nitrous oxideThe risk or severity of adverse effects can be increased when Quetiapine is combined with Nitrous oxide.Approved, Vet Approved
NorethisteroneThe serum concentration of Quetiapine can be decreased when it is combined with Norethisterone.Approved
NorfloxacinNorfloxacin may increase the QTc-prolonging activities of Quetiapine.Approved
NormethadoneThe risk or severity of adverse effects can be increased when Quetiapine is combined with Normethadone.Approved, Illicit
NortriptylineNortriptyline may increase the QTc-prolonging activities of Quetiapine.Approved
ObinutuzumabThe risk or severity of adverse effects can be increased when Quetiapine is combined with Obinutuzumab.Approved
OctreotideOctreotide may increase the QTc-prolonging activities of Quetiapine.Approved, Investigational
OfloxacinOfloxacin may increase the QTc-prolonging activities of Quetiapine.Approved
OlanzapineOlanzapine may increase the QTc-prolonging activities of Quetiapine.Approved, Investigational
OlaparibThe metabolism of Quetiapine can be decreased when combined with Olaparib.Approved
OlmesartanThe risk or severity of adverse effects can be increased when Olmesartan is combined with Quetiapine.Approved, Investigational
OlodaterolOlodaterol may increase the QTc-prolonging activities of Quetiapine.Approved
OlopatadineThe risk or severity of adverse effects can be increased when Quetiapine is combined with Olopatadine.Approved
OmeprazoleThe serum concentration of Quetiapine can be increased when it is combined with Omeprazole.Approved, Investigational, Vet Approved
OndansetronOndansetron may increase the QTc-prolonging activities of Quetiapine.Approved
OpiumThe risk or severity of adverse effects can be increased when Quetiapine is combined with Opium.Approved, Illicit
OrphenadrineQuetiapine may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Approved
OsanetantThe risk or severity of adverse effects can be increased when Quetiapine is combined with Osanetant.Investigational
OsimertinibThe serum concentration of Quetiapine can be increased when it is combined with Osimertinib.Approved
OxazepamThe risk or severity of adverse effects can be increased when Oxazepam is combined with Quetiapine.Approved
OxetacaineThe risk or severity of adverse effects can be increased when Quetiapine is combined with Oxetacaine.Investigational
OxprenololThe risk or severity of adverse effects can be increased when Quetiapine is combined with Oxprenolol.Approved
OxybuprocaineThe risk or severity of adverse effects can be increased when Oxybuprocaine is combined with Quetiapine.Approved
OxycodoneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Quetiapine.Approved, Illicit, Investigational
OxymorphoneThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Quetiapine.Approved, Investigational, Vet Approved
OxytocinOxytocin may increase the QTc-prolonging activities of Quetiapine.Approved, Vet Approved
P-NitrophenolThe serum concentration of Quetiapine can be increased when it is combined with P-Nitrophenol.Experimental
PaclitaxelThe serum concentration of Quetiapine can be increased when it is combined with Paclitaxel.Approved, Vet Approved
PalbociclibThe serum concentration of Quetiapine can be increased when it is combined with Palbociclib.Approved
PaliperidoneQuetiapine may increase the QTc-prolonging activities of Paliperidone.Approved
Palmitic AcidThe serum concentration of Quetiapine can be increased when it is combined with Palmitic Acid.Experimental
PanobinostatThe serum concentration of Quetiapine can be increased when it is combined with Panobinostat.Approved, Investigational
PantoprazoleThe serum concentration of Quetiapine can be increased when it is combined with Pantoprazole.Approved
PapaverineThe risk or severity of adverse effects can be increased when Papaverine is combined with Quetiapine.Approved
ParaldehydeQuetiapine may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.Approved
ParoxetineParoxetine may increase the QTc-prolonging activities of Quetiapine.Approved, Investigational
PasireotidePasireotide may increase the QTc-prolonging activities of Quetiapine.Approved
PazopanibPazopanib may increase the QTc-prolonging activities of Quetiapine.Approved
Peginterferon alfa-2bThe serum concentration of Quetiapine can be decreased when it is combined with Peginterferon alfa-2b.Approved
PenbutololThe risk or severity of adverse effects can be increased when Quetiapine is combined with Penbutolol.Approved, Investigational
PentamidinePentamidine may increase the QTc-prolonging activities of Quetiapine.Approved
PentazocineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Quetiapine.Approved, Vet Approved
PentobarbitalThe serum concentration of Quetiapine can be decreased when it is combined with Pentobarbital.Approved, Vet Approved
PerampanelPerampanel may increase the central nervous system depressant (CNS depressant) activities of Quetiapine.Approved
PerazineThe risk or severity of adverse effects can be increased when Quetiapine is combined with Perazine.Investigational
PerflutrenPerflutren may increase the QTc-prolonging activities of Quetiapine.Approved
PerindoprilThe risk or severity of adverse effects can be increased when Perindopril is combined with Quetiapine.Approved
PerospironeThe risk or severity of adverse effects can be increased when Quetiapine is combined with Perospirone.Approved
PerphenazineThe risk or severity of adverse effects can be increased when Perphenazine is combined with Quetiapine.Approved
PethidineThe risk or severity of adverse effects can be increased when Pethidine is combined with Quetiapine.Approved
PhenelzineThe risk or severity of adverse effects can be increased when Phenelzine is combined with Quetiapine.Approved
PhenforminThe therapeutic efficacy of Phenformin can be decreased when used in combination with Quetiapine.Approved, Withdrawn
PhenobarbitalThe serum concentration of Quetiapine can be decreased when it is combined with Phenobarbital.Approved
PhenoxybenzamineThe risk or severity of adverse effects can be increased when Quetiapine is combined with Phenoxybenzamine.Approved
PhenoxyethanolThe risk or severity of adverse effects can be increased when Quetiapine is combined with Phenoxyethanol.Approved
PhentermineQuetiapine may decrease the stimulatory activities of Phentermine.Approved, Illicit
PhentolamineThe risk or severity of adverse effects can be increased when Quetiapine is combined with Phentolamine.Approved
PhenytoinThe serum concentration of Quetiapine can be decreased when it is combined with Phenytoin.Approved, Vet Approved
PimozidePimozide may increase the QTc-prolonging activities of Quetiapine.Approved
PindololThe risk or severity of adverse effects can be increased when Pindolol is combined with Quetiapine.Approved
PioglitazoneThe therapeutic efficacy of Pioglitazone can be decreased when used in combination with Quetiapine.Approved, Investigational
PipamperoneThe risk or severity of adverse effects can be increased when Quetiapine is combined with Pipamperone.Approved
PipotiazineThe risk or severity of adverse effects can be increased when Quetiapine is combined with Pipotiazine.Approved
PiribedilThe therapeutic efficacy of Piribedil can be decreased when used in combination with Quetiapine.Investigational
PiritramideThe risk or severity of adverse effects can be increased when Quetiapine is combined with Piritramide.Investigational
PizotifenThe risk or severity of adverse effects can be increased when Quetiapine is combined with Pizotifen.Approved
Platelet Activating FactorThe serum concentration of Quetiapine can be decreased when it is combined with Platelet Activating Factor.Experimental
PomalidomideThe risk or severity of adverse effects can be increased when Quetiapine is combined with Pomalidomide.Approved
PonatinibThe serum concentration of Quetiapine can be increased when it is combined with Ponatinib.Approved
PosaconazoleThe serum concentration of Quetiapine can be increased when it is combined with Posaconazole.Approved, Investigational, Vet Approved
PramipexoleQuetiapine may increase the sedative activities of Pramipexole.Approved, Investigational
PramlintideThe therapeutic efficacy of Pramlintide can be decreased when used in combination with Quetiapine.Approved, Investigational
PramocaineThe risk or severity of adverse effects can be increased when Quetiapine is combined with Pramocaine.Approved
PravastatinThe serum concentration of Quetiapine can be increased when it is combined with Pravastatin.Approved
PrazepamThe risk or severity of adverse effects can be increased when Quetiapine is combined with Prazepam.Approved, Illicit
PrazosinThe risk or severity of adverse effects can be increased when Prazosin is combined with Quetiapine.Approved
PrednisoneThe serum concentration of Quetiapine can be increased when it is combined with Prednisone.Approved, Vet Approved
PregabalinThe risk or severity of adverse effects can be increased when Pregabalin is combined with Quetiapine.Approved, Illicit, Investigational
PregnanoloneThe risk or severity of adverse effects can be increased when Quetiapine is combined with Pregnanolone.Investigational
PrilocaineThe risk or severity of adverse effects can be increased when Prilocaine is combined with Quetiapine.Approved
PrimaquinePrimaquine may increase the QTc-prolonging activities of Quetiapine.Approved
PrimidoneThe serum concentration of Quetiapine can be decreased when it is combined with Primidone.Approved, Vet Approved
ProbenecidThe serum concentration of Quetiapine can be increased when it is combined with Probenecid.Approved
ProcainamideProcainamide may increase the QTc-prolonging activities of Quetiapine.Approved
ProcaineThe risk or severity of adverse effects can be increased when Procaine is combined with Quetiapine.Approved, Investigational, Vet Approved
ProcarbazineThe risk or severity of adverse effects can be increased when Procarbazine is combined with Quetiapine.Approved
ProchlorperazineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Quetiapine.Approved, Vet Approved
ProgesteroneThe serum concentration of Quetiapine can be decreased when it is combined with Progesterone.Approved, Vet Approved
PromazinePromazine may increase the QTc-prolonging activities of Quetiapine.Approved, Vet Approved
PromethazinePromethazine may increase the QTc-prolonging activities of Quetiapine.Approved
PropafenonePropafenone may increase the QTc-prolonging activities of Quetiapine.Approved
ProparacaineThe risk or severity of adverse effects can be increased when Proparacaine is combined with Quetiapine.Approved, Vet Approved
PropofolPropofol may increase the QTc-prolonging activities of Quetiapine.Approved, Investigational, Vet Approved
PropoxycaineThe risk or severity of adverse effects can be increased when Quetiapine is combined with Propoxycaine.Approved
PropranololThe risk or severity of adverse effects can be increased when Propranolol is combined with Quetiapine.Approved, Investigational
ProtriptylineProtriptyline may increase the QTc-prolonging activities of Quetiapine.Approved
PSD502The risk or severity of adverse effects can be increased when Quetiapine is combined with PSD502.Investigational
PseudoephedrineQuetiapine may decrease the stimulatory activities of Pseudoephedrine.Approved
QuazepamThe risk or severity of adverse effects can be increased when Quetiapine is combined with Quazepam.Approved, Illicit
QuercetinThe serum concentration of Quetiapine can be increased when it is combined with Quercetin.Experimental
QuinacrineThe serum concentration of Quetiapine can be increased when it is combined with Quinacrine.Approved
QuinagolideThe therapeutic efficacy of Quinagolide can be decreased when used in combination with Quetiapine.Approved
QuinaprilThe risk or severity of adverse effects can be increased when Quinapril is combined with Quetiapine.Approved, Investigational
QuinidineQuinidine may increase the QTc-prolonging activities of Quetiapine.Approved
QuinineQuinine may increase the QTc-prolonging activities of Quetiapine.Approved
RacloprideThe risk or severity of adverse effects can be increased when Quetiapine is combined with Raclopride.Investigational
RamelteonThe risk or severity of adverse effects can be increased when Quetiapine is combined with Ramelteon.Approved, Investigational
RamiprilThe risk or severity of adverse effects can be increased when Ramipril is combined with Quetiapine.Approved
RanitidineThe serum concentration of Quetiapine can be increased when it is combined with Ranitidine.Approved
RanolazineThe serum concentration of Quetiapine can be increased when it is combined with Ranolazine.Approved, Investigational
RasagilineThe risk or severity of adverse effects can be increased when Rasagiline is combined with Quetiapine.Approved
ReboxetineThe serum concentration of Quetiapine can be increased when it is combined with Reboxetine.Approved, Investigational
RegorafenibThe serum concentration of Quetiapine can be increased when it is combined with Regorafenib.Approved
RemifentanilThe risk or severity of adverse effects can be increased when Remifentanil is combined with Quetiapine.Approved
RemoxiprideThe risk or severity of adverse effects can be increased when Remoxipride is combined with Quetiapine.Approved, Withdrawn
RepaglinideThe therapeutic efficacy of Repaglinide can be decreased when used in combination with Quetiapine.Approved, Investigational
ReserpineThe risk or severity of adverse effects can be increased when Reserpine is combined with Quetiapine.Approved
RifabutinThe serum concentration of Quetiapine can be decreased when it is combined with Rifabutin.Approved
RifampicinThe serum concentration of Quetiapine can be decreased when it is combined with Rifampicin.Approved
RifapentineThe serum concentration of Quetiapine can be decreased when it is combined with Rifapentine.Approved
RilpivirineRilpivirine may increase the QTc-prolonging activities of Quetiapine.Approved
RiociguatThe risk or severity of adverse effects can be increased when Quetiapine is combined with Riociguat.Approved
RisperidoneQuetiapine may increase the hypotensive activities of Risperidone.Approved, Investigational
RitanserinThe risk or severity of adverse effects can be increased when Quetiapine is combined with Ritanserin.Investigational
RitobegronQuetiapine may decrease the stimulatory activities of Ritobegron.Investigational
RitonavirThe serum concentration of Quetiapine can be increased when it is combined with Ritonavir.Approved, Investigational
RizatriptanThe risk or severity of adverse effects can be increased when Rizatriptan is combined with Quetiapine.Approved
RolapitantThe serum concentration of Quetiapine can be increased when it is combined with Rolapitant.Approved
RomifidineThe risk or severity of adverse effects can be increased when Quetiapine is combined with Romifidine.Vet Approved
RopiniroleQuetiapine may increase the sedative activities of Ropinirole.Approved, Investigational
RopivacaineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Quetiapine.Approved
RosiglitazoneThe therapeutic efficacy of Rosiglitazone can be decreased when used in combination with Quetiapine.Approved, Investigational
RotigotineQuetiapine may increase the sedative activities of Rotigotine.Approved
RufinamideThe risk or severity of adverse effects can be increased when Rufinamide is combined with Quetiapine.Approved
S-EthylisothioureaThe risk or severity of adverse effects can be increased when Quetiapine is combined with S-Ethylisothiourea.Experimental
SacubitrilThe risk or severity of adverse effects can be increased when Quetiapine is combined with Sacubitril.Approved
Sage 547The risk or severity of adverse effects can be increased when Quetiapine is combined with Sage 547.Investigational
SalbutamolSalbutamol may increase the QTc-prolonging activities of Quetiapine.Approved, Vet Approved
SalmeterolSalmeterol may increase the QTc-prolonging activities of Quetiapine.Approved
SaquinavirThe serum concentration of Quetiapine can be increased when it is combined with Saquinavir.Approved, Investigational
SaxagliptinThe therapeutic efficacy of Saxagliptin can be decreased when used in combination with Quetiapine.Approved
ScopolamineThe serum concentration of Quetiapine can be increased when it is combined with Scopolamine.Approved
SecobarbitalThe risk or severity of adverse effects can be increased when Secobarbital is combined with Quetiapine.Approved, Vet Approved
SelegilineThe serum concentration of Quetiapine can be increased when it is combined with Selegiline.Approved, Investigational, Vet Approved
SertindoleThe risk or severity of adverse effects can be increased when Quetiapine is combined with Sertindole.Approved, Withdrawn
SertralineSertraline may increase the QTc-prolonging activities of Quetiapine.Approved
SevofluraneSevoflurane may increase the QTc-prolonging activities of Quetiapine.Approved, Vet Approved
SildenafilThe metabolism of Quetiapine can be decreased when combined with Sildenafil.Approved, Investigational
SiltuximabThe serum concentration of Quetiapine can be decreased when it is combined with Siltuximab.Approved
SimeprevirThe serum concentration of Quetiapine can be increased when it is combined with Simeprevir.Approved
SimvastatinThe serum concentration of Quetiapine can be increased when it is combined with Simvastatin.Approved
SirolimusThe serum concentration of Quetiapine can be decreased when it is combined with Sirolimus.Approved, Investigational
SitagliptinThe therapeutic efficacy of Sitagliptin can be decreased when used in combination with Quetiapine.Approved, Investigational
Sodium NitriteThe risk or severity of adverse effects can be increased when Quetiapine is combined with Sodium Nitrite.Approved
Sodium oxybateSodium oxybate may increase the central nervous system depressant (CNS depressant) activities of Quetiapine.Approved
SolifenacinSolifenacin may increase the QTc-prolonging activities of Quetiapine.Approved
SorafenibSorafenib may increase the QTc-prolonging activities of Quetiapine.Approved, Investigational
SotalolSotalol may increase the QTc-prolonging activities of Quetiapine.Approved
SpironolactoneThe risk or severity of adverse effects can be increased when Spironolactone is combined with Quetiapine.Approved
St. John's WortQuetiapine may increase the serotonergic activities of St. John's Wort.Nutraceutical
StaurosporineThe serum concentration of Quetiapine can be increased when it is combined with Staurosporine.Experimental
StiripentolThe serum concentration of Quetiapine can be increased when it is combined with Stiripentol.Approved
StreptokinaseThe risk or severity of adverse effects can be increased when Quetiapine is combined with Streptokinase.Approved
StreptozocinThe serum concentration of Quetiapine can be decreased when it is combined with Streptozocin.Approved
SufentanilThe risk or severity of adverse effects can be increased when Sufentanil is combined with Quetiapine.Approved, Investigational
SulfamethoxazoleSulfamethoxazole may increase the QTc-prolonging activities of Quetiapine.Approved
SulfinpyrazoneThe serum concentration of Quetiapine can be increased when it is combined with Sulfinpyrazone.Approved
SulfisoxazoleSulfisoxazole may increase the QTc-prolonging activities of Quetiapine.Approved, Vet Approved
SulodexideThe therapeutic efficacy of Sulodexide can be decreased when used in combination with Quetiapine.Approved, Investigational
SulpirideThe risk or severity of adverse effects can be increased when Quetiapine is combined with Sulpiride.Approved
SumatriptanThe serum concentration of Quetiapine can be increased when it is combined with Sumatriptan.Approved, Investigational
SunitinibSunitinib may increase the QTc-prolonging activities of Quetiapine.Approved, Investigational
SuvorexantQuetiapine may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Approved
TacrineThe serum concentration of Quetiapine can be increased when it is combined with Tacrine.Withdrawn
TacrolimusThe serum concentration of Quetiapine can be decreased when it is combined with Tacrolimus.Approved, Investigational
TamoxifenTamoxifen may increase the QTc-prolonging activities of Quetiapine.Approved
TamsulosinThe risk or severity of adverse effects can be increased when Quetiapine is combined with Tamsulosin.Approved, Investigational
TandospironeThe risk or severity of adverse effects can be increased when Quetiapine is combined with Tandospirone.Investigational
TapentadolTapentadol may increase the central nervous system depressant (CNS depressant) activities of Quetiapine.Approved
TasimelteonThe risk or severity of adverse effects can be increased when Quetiapine is combined with Tasimelteon.Approved
Taurocholic AcidThe serum concentration of Quetiapine can be increased when it is combined with Taurocholic Acid.Experimental
Tedizolid PhosphateThe risk or severity of adverse effects can be increased when Tedizolid Phosphate is combined with Quetiapine.Approved
TelaprevirThe serum concentration of Quetiapine can be increased when it is combined with Telaprevir.Approved
TelavancinTelavancin may increase the QTc-prolonging activities of Quetiapine.Approved
TelithromycinThe serum concentration of Quetiapine can be increased when it is combined with Telithromycin.Approved
TelmisartanThe risk or severity of adverse effects can be increased when Telmisartan is combined with Quetiapine.Approved, Investigational
TemazepamThe risk or severity of adverse effects can be increased when Temazepam is combined with Quetiapine.Approved
TemsirolimusThe serum concentration of Quetiapine can be increased when it is combined with Temsirolimus.Approved
TerazosinThe risk or severity of adverse effects can be increased when Terazosin is combined with Quetiapine.Approved
TerbinafineThe metabolism of Quetiapine can be decreased when combined with Terbinafine.Approved, Investigational, Vet Approved
TerbutalineTerbutaline may increase the QTc-prolonging activities of Quetiapine.Approved
TerfenadineThe serum concentration of Quetiapine can be increased when it is combined with Terfenadine.Withdrawn
TesmilifeneThe serum concentration of Quetiapine can be decreased when it is combined with Tesmilifene.Investigational
TestosteroneThe serum concentration of Quetiapine can be increased when it is combined with Testosterone.Approved, Investigational
TetrabenazineThe risk or severity of adverse effects can be increased when Tetrabenazine is combined with Quetiapine.Approved
TetracaineThe risk or severity of adverse effects can be increased when Quetiapine is combined with Tetracaine.Approved, Vet Approved
TetrodotoxinThe risk or severity of adverse effects can be increased when Quetiapine is combined with Tetrodotoxin.Investigational
ThalidomideQuetiapine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Approved, Investigational, Withdrawn
ThiamylalThe risk or severity of adverse effects can be increased when Thiamylal is combined with Quetiapine.Approved, Vet Approved
ThiazolidinedioneThe therapeutic efficacy of Thiazolidinedione can be decreased when used in combination with Quetiapine.Investigational
ThiopentalThe risk or severity of adverse effects can be increased when Thiopental is combined with Quetiapine.Approved, Vet Approved
ThioridazineThe serum concentration of Thioridazine can be increased when it is combined with Quetiapine.Approved
ThiothixeneThiothixene may increase the QTc-prolonging activities of Quetiapine.Approved
TiagabineThe risk or severity of adverse effects can be increased when Quetiapine is combined with Tiagabine.Approved
TiaprideThe risk or severity of adverse effects can be increased when Quetiapine is combined with Tiapride.Investigational
TicagrelorThe serum concentration of Quetiapine can be increased when it is combined with Ticagrelor.Approved
TiclopidineThe metabolism of Quetiapine can be decreased when combined with Ticlopidine.Approved
TiletamineThe risk or severity of adverse effects can be increased when Quetiapine is combined with Tiletamine.Vet Approved
TimololThe risk or severity of adverse effects can be increased when Timolol is combined with Quetiapine.Approved
TipranavirThe metabolism of Quetiapine can be decreased when combined with Tipranavir.Approved, Investigational
TizanidineTizanidine may increase the QTc-prolonging activities of Quetiapine.Approved
TocilizumabThe serum concentration of Quetiapine can be decreased when it is combined with Tocilizumab.Approved
TolazamideThe therapeutic efficacy of Tolazamide can be decreased when used in combination with Quetiapine.Approved
TolazolineThe risk or severity of adverse effects can be increased when Quetiapine is combined with Tolazoline.Approved, Vet Approved
TolbutamideThe therapeutic efficacy of Tolbutamide can be decreased when used in combination with Quetiapine.Approved
TolcaponeThe risk or severity of adverse effects can be increased when Quetiapine is combined with Tolcapone.Approved, Withdrawn
TolterodineTolterodine may increase the QTc-prolonging activities of Quetiapine.Approved, Investigational
TolvaptanThe serum concentration of Quetiapine can be increased when it is combined with Tolvaptan.Approved
TopiramateThe risk or severity of adverse effects can be increased when Quetiapine is combined with Topiramate.Approved
TorasemideThe risk or severity of adverse effects can be increased when Torasemide is combined with Quetiapine.Approved
ToremifeneToremifene may increase the QTc-prolonging activities of Quetiapine.Approved, Investigational
TramadolThe risk or severity of adverse effects can be increased when Tramadol is combined with Quetiapine.Approved, Investigational
TrandolaprilThe risk or severity of adverse effects can be increased when Trandolapril is combined with Quetiapine.Approved
Trans-2-PhenylcyclopropylamineThe risk or severity of adverse effects can be increased when Quetiapine is combined with Trans-2-Phenylcyclopropylamine.Experimental
TranylcypromineThe metabolism of Quetiapine can be decreased when combined with Tranylcypromine.Approved
TrazodoneTrazodone may increase the QTc-prolonging activities of Quetiapine.Approved, Investigational
TreprostinilTreprostinil may increase the QTc-prolonging activities of Quetiapine.Approved, Investigational
TretinoinThe risk or severity of adverse effects can be increased when Quetiapine is combined with Tretinoin.Approved, Investigational, Nutraceutical
TriamtereneThe risk or severity of adverse effects can be increased when Triamterene is combined with Quetiapine.Approved
TriazolamThe risk or severity of adverse effects can be increased when Triazolam is combined with Quetiapine.Approved
TrifluoperazineThe serum concentration of Quetiapine can be increased when it is combined with Trifluoperazine.Approved
TriflupromazineThe serum concentration of Quetiapine can be increased when it is combined with Triflupromazine.Approved, Vet Approved
TrimethoprimTrimethoprim may increase the QTc-prolonging activities of Quetiapine.Approved, Vet Approved
TrimipramineTrimipramine may increase the QTc-prolonging activities of Quetiapine.Approved
TriprolidineThe risk or severity of adverse effects can be increased when Quetiapine is combined with Triprolidine.Approved
TriptorelinTriptorelin may increase the QTc-prolonging activities of Quetiapine.Approved, Vet Approved
TroglitazoneThe therapeutic efficacy of Troglitazone can be decreased when used in combination with Quetiapine.Withdrawn
TroleandomycinThe serum concentration of Quetiapine can be increased when it is combined with Troleandomycin.Approved
Uc1010The risk or severity of adverse effects can be increased when Quetiapine is combined with Uc1010.Investigational
Valproic AcidThe risk or severity of adverse effects can be increased when Valproic Acid is combined with Quetiapine.Approved, Investigational
ValsartanThe risk or severity of adverse effects can be increased when Valsartan is combined with Quetiapine.Approved, Investigational
VandetanibQuetiapine may increase the QTc-prolonging activities of Vandetanib.Approved
VardenafilVardenafil may increase the QTc-prolonging activities of Quetiapine.Approved
VemurafenibQuetiapine may increase the QTc-prolonging activities of Vemurafenib.Approved
VenlafaxineVenlafaxine may increase the QTc-prolonging activities of Quetiapine.Approved
VerapamilThe risk or severity of adverse effects can be increased when Verapamil is combined with Quetiapine.Approved
VigabatrinThe risk or severity of adverse effects can be increased when Quetiapine is combined with Vigabatrin.Approved
VilanterolVilanterol may increase the QTc-prolonging activities of Quetiapine.Approved
VilazodoneThe risk or severity of adverse effects can be increased when Vilazodone is combined with Quetiapine.Approved
VildagliptinThe therapeutic efficacy of Vildagliptin can be decreased when used in combination with Quetiapine.Approved, Investigational
VinblastineThe serum concentration of Quetiapine can be decreased when it is combined with Vinblastine.Approved
VincristineThe serum concentration of Quetiapine can be decreased when it is combined with Vincristine.Approved, Investigational
VinorelbineThe serum concentration of Quetiapine can be increased when it is combined with Vinorelbine.Approved, Investigational
VogliboseThe therapeutic efficacy of Voglibose can be decreased when used in combination with Quetiapine.Approved, Investigational
VoriconazoleThe serum concentration of Quetiapine can be increased when it is combined with Voriconazole.Approved, Investigational
VorinostatVorinostat may increase the QTc-prolonging activities of Quetiapine.Approved, Investigational
VortioxetineThe risk or severity of adverse effects can be increased when Quetiapine is combined with Vortioxetine.Approved
XylazineThe risk or severity of adverse effects can be increased when Quetiapine is combined with Xylazine.Vet Approved
ZaleplonThe risk or severity of adverse effects can be increased when Zaleplon is combined with Quetiapine.Approved, Illicit, Investigational
ZiconotideThe risk or severity of adverse effects can be increased when Quetiapine is combined with Ziconotide.Approved
ZimelidineThe serum concentration of Quetiapine can be increased when it is combined with Zimelidine.Withdrawn
ZiprasidoneZiprasidone may increase the QTc-prolonging activities of Quetiapine.Approved
ZolazepamThe risk or severity of adverse effects can be increased when Quetiapine is combined with Zolazepam.Vet Approved
ZolmitriptanThe risk or severity of adverse effects can be increased when Zolmitriptan is combined with Quetiapine.Approved, Investigational
ZolpidemQuetiapine may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Approved
ZonisamideThe risk or severity of adverse effects can be increased when Quetiapine is combined with Zonisamide.Approved, Investigational
ZopicloneThe risk or severity of adverse effects can be increased when Zopiclone is combined with Quetiapine.Approved
ZotepineThe risk or severity of adverse effects can be increased when Quetiapine is combined with Zotepine.Approved
ZuclopenthixolQuetiapine may increase the QTc-prolonging activities of Zuclopenthixol.Approved, Investigational
Food Interactions
  • Avoid alcohol.
  • Take without regard to meals.
References
Synthesis Reference

DrugSyn.org

US4879288
General References
  1. Dev V, Raniwalla J: Quetiapine: a review of its safety in the management of schizophrenia. Drug Saf. 2000 Oct;23(4):295-307. [PubMed:11051217 ]
  2. Mukaddes NM, Abali O: Quetiapine treatment of children and adolescents with Tourette's disorder. J Child Adolesc Psychopharmacol. 2003 Fall;13(3):295-9. [PubMed:14642017 ]
  3. Tallerico T, Novak G, Liu IS, Ulpian C, Seeman P: Schizophrenia: elevated mRNA for dopamine D2(Longer) receptors in frontal cortex. Brain Res Mol Brain Res. 2001 Mar 5;87(2):160-5. [PubMed:11245917 ]
  4. Urichuk L, Prior TI, Dursun S, Baker G: Metabolism of atypical antipsychotics: involvement of cytochrome p450 enzymes and relevance for drug-drug interactions. Curr Drug Metab. 2008 Jun;9(5):410-8. [PubMed:18537577 ]
External Links
ATC CodesN05AH04
AHFS Codes
  • 28:16.08.04
PDB EntriesNot Available
FDA labelDownload (273 KB)
MSDSDownload (57.1 KB)
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9155
Blood Brain Barrier+0.9906
Caco-2 permeable-0.6037
P-glycoprotein substrateSubstrate0.8424
P-glycoprotein inhibitor IInhibitor0.9117
P-glycoprotein inhibitor IIInhibitor0.9325
Renal organic cation transporterInhibitor0.5554
CYP450 2C9 substrateNon-substrate0.6438
CYP450 2D6 substrateSubstrate0.8919
CYP450 3A4 substrateNon-substrate0.6049
CYP450 1A2 substrateInhibitor0.5744
CYP450 2C9 inhibitorNon-inhibitor0.6305
CYP450 2D6 inhibitorInhibitor0.588
CYP450 2C19 inhibitorNon-inhibitor0.7033
CYP450 3A4 inhibitorInhibitor0.7961
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.5375
Ames testNon AMES toxic0.7479
CarcinogenicityNon-carcinogens0.869
BiodegradationNot ready biodegradable1.0
Rat acute toxicity2.6537 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9483
hERG inhibition (predictor II)Inhibitor0.8684
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
ManufacturersNot Available
Packagers
Dosage forms
FormRouteStrength
Tablet, multilayer, extended releaseOral100 mg
Tablet, multilayer, extended releaseOral200 mg
Tablet, multilayer, extended releaseOral25 mg
Tablet, multilayer, extended releaseOral300 mg
TabletOral50 mg
TabletOral100 mg/1
TabletOral150 mg/1
TabletOral200 mg/1
TabletOral25 mg/1
TabletOral300 mg/1
TabletOral400 mg/1
TabletOral50 mg/1
Tablet, film coatedOral100 mg/1
Tablet, film coatedOral150 mg/1
Tablet, film coatedOral200 mg/1
Tablet, film coatedOral25 mg/1
Tablet, film coatedOral300 mg/1
Tablet, film coatedOral400 mg/1
Tablet, film coatedOral50 mg/1
TabletOral300 mg
TabletOral100 mg
TabletOral200 mg
TabletOral25 mg
Kit
Tablet, extended releaseOral150 mg
Tablet, extended releaseOral150 mg/1
Tablet, extended releaseOral200 mg
Tablet, extended releaseOral200 mg/1
Tablet, extended releaseOral300 mg/1
Tablet, extended releaseOral300 mg
Tablet, extended releaseOral400 mg
Tablet, extended releaseOral400 mg/1
Tablet, extended releaseOral50 mg/1
Tablet, extended releaseOral50 mg
TabletOral150 mg
Prices
Unit descriptionCostUnit
Seroquel 400 mg tablet16.71USD tablet
Seroquel xr 400 mg tablet14.82USD tablet
Seroquel 300 mg tablet14.21USD tablet
Seroquel xr 300 mg tablet12.61USD tablet
Seroquel 200 mg tablet10.84USD tablet
SEROquel XR 200 mg 24 Hour tablet10.0USD tablet
Seroquel xr 200 mg tablet9.62USD tablet
SEROquel XR 150 mg 24 Hour tablet9.09USD tablet
Seroquel xr 150 mg tablet8.74USD tablet
Seroquel 100 mg tablet5.75USD tablet
Seroquel 50 mg tablet5.5USD tablet
SEROquel XR 50 mg 24 Hour tablet5.06USD tablet
Seroquel xr 50 mg tablet4.87USD tablet
Seroquel 300 mg Tablet4.35USD tablet
Seroquel 25 mg tablet3.35USD tablet
Seroquel 200 mg Tablet2.98USD tablet
Apo-Quetiapine 300 mg Tablet2.44USD tablet
Co Quetiapine 300 mg Tablet2.44USD tablet
Jamp-Quetiapine 300 mg Tablet2.44USD tablet
Mylan-Quetiapine 300 mg Tablet2.44USD tablet
Novo-Quetiapine 300 mg Tablet2.44USD tablet
Pms-Quetiapine 300 mg Tablet2.44USD tablet
Ratio-Quetiapine 300 mg Tablet2.44USD tablet
Sandoz Quetiapine 300 mg Tablet2.44USD tablet
Apo-Quetiapine 200 mg Tablet1.67USD tablet
Co Quetiapine 200 mg Tablet1.67USD tablet
Jamp-Quetiapine 200 mg Tablet1.67USD tablet
Mylan-Quetiapine 200 mg Tablet1.67USD tablet
Novo-Quetiapine 200 mg Tablet1.67USD tablet
Pms-Quetiapine 200 mg Tablet1.67USD tablet
Ratio-Quetiapine 200 mg Tablet1.67USD tablet
Sandoz Quetiapine 200 mg Tablet1.67USD tablet
Seroquel 100 mg Tablet1.48USD tablet
Novo-Quetiapine 150 mg Tablet1.42USD tablet
Apo-Quetiapine 100 mg Tablet0.83USD tablet
Co Quetiapine 100 mg Tablet0.83USD tablet
Jamp-Quetiapine 100 mg Tablet0.83USD tablet
Mylan-Quetiapine 100 mg Tablet0.83USD tablet
Novo-Quetiapine 100 mg Tablet0.83USD tablet
Pms-Quetiapine 100 mg Tablet0.83USD tablet
Ratio-Quetiapine 100 mg Tablet0.83USD tablet
Sandoz Quetiapine 100 mg Tablet0.83USD tablet
Seroquel 25 mg Tablet0.56USD tablet
Apo-Quetiapine 25 mg Tablet0.31USD tablet
Co Quetiapine 25 mg Tablet0.31USD tablet
Jamp-Quetiapine 25 mg Tablet0.31USD tablet
Mylan-Quetiapine 25 mg Tablet0.31USD tablet
Novo-Quetiapine 25 mg Tablet0.31USD tablet
Pms-Quetiapine 25 mg Tablet0.31USD tablet
Ratio-Quetiapine 25 mg Tablet0.31USD tablet
Sandoz Quetiapine 25 mg Tablet0.31USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
CA2251944 No2007-04-102017-05-27Canada
US4879288 No1994-09-262011-09-26Us
US5948437 Yes1997-11-282017-11-28Us
Properties
StateSolid
Experimental Properties
PropertyValueSource
water solubilityModerateNot Available
logP2.8Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.0403 mg/mLALOGPS
logP2.93ALOGPS
logP2.81ChemAxon
logS-4ALOGPS
pKa (Strongest Acidic)15.12ChemAxon
pKa (Strongest Basic)7.06ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count5ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area48.3 Å2ChemAxon
Rotatable Bond Count5ChemAxon
Refractivity114.09 m3·mol-1ChemAxon
Polarizability42.78 Å3ChemAxon
Number of Rings4ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as dibenzothiazepines. These are compounds containing a dibenzothiazepine moiety, which consists of two benzene connected by a thiazepine ring.
KingdomOrganic compounds
Super ClassOrganoheterocyclic compounds
ClassBenzothiazepines
Sub ClassDibenzothiazepines
Direct ParentDibenzothiazepines
Alternative Parents
Substituents
  • Dibenzothiazepine
  • Diarylthioether
  • N-alkylpiperazine
  • Imidolactam
  • Benzenoid
  • Piperazine
  • 1,4-diazinane
  • Tertiary aliphatic amine
  • Tertiary amine
  • Azacycle
  • Organic 1,3-dipolar compound
  • Propargyl-type 1,3-dipolar organic compound
  • Thioether
  • Ether
  • Dialkyl ether
  • Carboxylic acid amidine
  • Amidine
  • Hydrocarbon derivative
  • Primary alcohol
  • Organooxygen compound
  • Organonitrogen compound
  • Amine
  • Alcohol
  • Aromatic heteropolycyclic compound
Molecular FrameworkAromatic heteropolycyclic compounds
External Descriptors

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
antagonist
General Function:
Virus receptor activity
Specific Function:
G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for various drugs and psychoactive substances, including mescaline, psilocybin, 1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane (DOI) and lysergic acid diethylamide (LSD). Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates...
Gene Name:
HTR2A
Uniprot ID:
P28223
Molecular Weight:
52602.58 Da
References
  1. Goldstein JM: Quetiapine fumarate (Seroquel): a new atypical antipsychotic. Drugs Today (Barc). 1999 Mar;35(3):193-210. [PubMed:12973385 ]
  2. McIntyre RS, Soczynska JK, Woldeyohannes HO, Alsuwaidan M, Konarski JZ: A preclinical and clinical rationale for quetiapine in mood syndromes. Expert Opin Pharmacother. 2007 Jun;8(9):1211-9. [PubMed:17563257 ]
  3. Richelson E, Souder T: Binding of antipsychotic drugs to human brain receptors focus on newer generation compounds. Life Sci. 2000 Nov 24;68(1):29-39. [PubMed:11132243 ]
  4. Yatham LN, Goldstein JM, Vieta E, Bowden CL, Grunze H, Post RM, Suppes T, Calabrese JR: Atypical antipsychotics in bipolar depression: potential mechanisms of action. J Clin Psychiatry. 2005;66 Suppl 5:40-8. [PubMed:16038601 ]
  5. Nasrallah HA: Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles. Mol Psychiatry. 2008 Jan;13(1):27-35. Epub 2007 Sep 11. [PubMed:17848919 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
antagonist
General Function:
Potassium channel regulator activity
Specific Function:
Dopamine receptor whose activity is mediated by G proteins which inhibit adenylyl cyclase.
Gene Name:
DRD2
Uniprot ID:
P14416
Molecular Weight:
50618.91 Da
References
  1. Kapur S, Zipursky R, Jones C, Shammi CS, Remington G, Seeman P: A positron emission tomography study of quetiapine in schizophrenia: a preliminary finding of an antipsychotic effect with only transiently high dopamine D2 receptor occupancy. Arch Gen Psychiatry. 2000 Jun;57(6):553-9. [PubMed:10839333 ]
  2. Richelson E, Souder T: Binding of antipsychotic drugs to human brain receptors focus on newer generation compounds. Life Sci. 2000 Nov 24;68(1):29-39. [PubMed:11132243 ]
  3. Seeman P: Atypical antipsychotics: mechanism of action. Can J Psychiatry. 2002 Feb;47(1):27-38. [PubMed:11873706 ]
  4. Nasrallah HA: Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles. Mol Psychiatry. 2008 Jan;13(1):27-35. Epub 2007 Sep 11. [PubMed:17848919 ]
  5. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Serotonin receptor activity
Specific Function:
G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for various drugs and psychoactive substances. Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of down-stream effectors, such as adenylate cyclase. Beta-arrestin family members inhibit signaling via G pro...
Gene Name:
HTR1A
Uniprot ID:
P08908
Molecular Weight:
46106.335 Da
References
  1. Ichikawa J, Li Z, Dai J, Meltzer HY: Atypical antipsychotic drugs, quetiapine, iloperidone, and melperone, preferentially increase dopamine and acetylcholine release in rat medial prefrontal cortex: role of 5-HT1A receptor agonism. Brain Res. 2002 Nov 29;956(2):349-57. [PubMed:12445705 ]
  2. McIntyre RS, Soczynska JK, Woldeyohannes HO, Alsuwaidan M, Konarski JZ: A preclinical and clinical rationale for quetiapine in mood syndromes. Expert Opin Pharmacother. 2007 Jun;8(9):1211-9. [PubMed:17563257 ]
  3. Richelson E, Souder T: Binding of antipsychotic drugs to human brain receptors focus on newer generation compounds. Life Sci. 2000 Nov 24;68(1):29-39. [PubMed:11132243 ]
  4. Wood MD, Scott C, Clarke K, Cato KJ, Patel N, Heath J, Worby A, Gordon L, Campbell L, Riley G, Davies CH, Gribble A, Jones DN: Pharmacological profile of antipsychotics at monoamine receptors: atypicality beyond 5-HT2A receptor blockade. CNS Neurol Disord Drug Targets. 2006 Aug;5(4):445-52. [PubMed:16918396 ]
  5. Nasrallah HA: Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles. Mol Psychiatry. 2008 Jan;13(1):27-35. Epub 2007 Sep 11. [PubMed:17848919 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
other/unknown
General Function:
Serotonin receptor activity
Specific Function:
G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for ergot alkaloid derivatives, various anxiolytic and antidepressant drugs and other psychoactive substances, such as lysergic acid diethylamide (LSD). Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of ...
Gene Name:
HTR1B
Uniprot ID:
P28222
Molecular Weight:
43567.535 Da
References
  1. Nasrallah HA: Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles. Mol Psychiatry. 2008 Jan;13(1):27-35. Epub 2007 Sep 11. [PubMed:17848919 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
other/unknown
General Function:
Serotonin receptor activity
Specific Function:
G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for ergot alkaloid derivatives, various anxiolytic and antidepressant drugs and other psychoactive substances. Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of down-stream effectors, such as adenylate c...
Gene Name:
HTR1D
Uniprot ID:
P28221
Molecular Weight:
41906.38 Da
References
  1. Richelson E, Souder T: Binding of antipsychotic drugs to human brain receptors focus on newer generation compounds. Life Sci. 2000 Nov 24;68(1):29-39. [PubMed:11132243 ]
  2. Nasrallah HA: Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles. Mol Psychiatry. 2008 Jan;13(1):27-35. Epub 2007 Sep 11. [PubMed:17848919 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
other/unknown
General Function:
Serotonin receptor activity
Specific Function:
G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for various alkaloids and psychoactive substances. Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of down-stream effectors, such as adenylate cyclase. Signaling inhibits adenylate cyclase activity.
Gene Name:
HTR1E
Uniprot ID:
P28566
Molecular Weight:
41681.57 Da
References
  1. Nasrallah HA: Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles. Mol Psychiatry. 2008 Jan;13(1):27-35. Epub 2007 Sep 11. [PubMed:17848919 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Serotonin receptor activity
Specific Function:
G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for various drugs and psychoactive substances, including ergot alkaloid derivatives, 1-2,5,-dimethoxy-4-iodophenyl-2-aminopropane (DOI) and lysergic acid diethylamide (LSD). Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modul...
Gene Name:
HTR2C
Uniprot ID:
P28335
Molecular Weight:
51820.705 Da
References
  1. Richelson E, Souder T: Binding of antipsychotic drugs to human brain receptors focus on newer generation compounds. Life Sci. 2000 Nov 24;68(1):29-39. [PubMed:11132243 ]
  2. Nasrallah HA: Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles. Mol Psychiatry. 2008 Jan;13(1):27-35. Epub 2007 Sep 11. [PubMed:17848919 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
other/unknown
General Function:
Voltage-gated potassium channel activity
Specific Function:
This is one of the several different receptors for 5-hydroxytryptamine (serotonin), a biogenic hormone that functions as a neurotransmitter, a hormone, and a mitogen. This receptor is a ligand-gated ion channel, which when activated causes fast, depolarizing responses in neurons. It is a cation-specific, but otherwise relatively nonselective, ion channel.
Gene Name:
HTR3A
Uniprot ID:
P46098
Molecular Weight:
55279.835 Da
References
  1. Nasrallah HA: Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles. Mol Psychiatry. 2008 Jan;13(1):27-35. Epub 2007 Sep 11. [PubMed:17848919 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
other/unknown
General Function:
Serotonin receptor activity
Specific Function:
This is one of the several different receptors for 5-hydroxytryptamine (serotonin), a biogenic hormone that functions as a neurotransmitter, a hormone, and a mitogen. The activity of this receptor is mediated by G proteins that stimulate adenylate cyclase. It has a high affinity for tricyclic psychotropic drugs (By similarity). Controls pyramidal neurons migration during corticogenesis, through...
Gene Name:
HTR6
Uniprot ID:
P50406
Molecular Weight:
46953.625 Da
References
  1. Nasrallah HA: Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles. Mol Psychiatry. 2008 Jan;13(1):27-35. Epub 2007 Sep 11. [PubMed:17848919 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Serotonin receptor activity
Specific Function:
This is one of the several different receptors for 5-hydroxytryptamine (serotonin), a biogenic hormone that functions as a neurotransmitter, a hormone, and a mitogen. The activity of this receptor is mediated by G proteins that stimulate adenylate cyclase.
Gene Name:
HTR7
Uniprot ID:
P34969
Molecular Weight:
53554.43 Da
References
  1. Nasrallah HA: Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles. Mol Psychiatry. 2008 Jan;13(1):27-35. Epub 2007 Sep 11. [PubMed:17848919 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
G-protein coupled amine receptor activity
Specific Function:
Dopamine receptor whose activity is mediated by G proteins which activate adenylyl cyclase.
Gene Name:
DRD1
Uniprot ID:
P21728
Molecular Weight:
49292.765 Da
References
  1. Nasrallah HA: Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles. Mol Psychiatry. 2008 Jan;13(1):27-35. Epub 2007 Sep 11. [PubMed:17848919 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
G-protein coupled amine receptor activity
Specific Function:
Dopamine receptor whose activity is mediated by G proteins which activate adenylyl cyclase.
Gene Name:
DRD5
Uniprot ID:
P21918
Molecular Weight:
52950.5 Da
References
  1. Nasrallah HA: Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles. Mol Psychiatry. 2008 Jan;13(1):27-35. Epub 2007 Sep 11. [PubMed:17848919 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
G-protein coupled amine receptor activity
Specific Function:
Dopamine receptor whose activity is mediated by G proteins which inhibit adenylyl cyclase. Promotes cell proliferation.
Gene Name:
DRD3
Uniprot ID:
P35462
Molecular Weight:
44224.335 Da
References
  1. Nasrallah HA: Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles. Mol Psychiatry. 2008 Jan;13(1):27-35. Epub 2007 Sep 11. [PubMed:17848919 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Sh3 domain binding
Specific Function:
Dopamine receptor responsible for neuronal signaling in the mesolimbic system of the brain, an area of the brain that regulates emotion and complex behavior. Its activity is mediated by G proteins which inhibit adenylyl cyclase. Modulates the circadian rhythm of contrast sensitivity by regulating the rhythmic expression of NPAS2 in the retinal ganglion cells (By similarity).
Gene Name:
DRD4
Uniprot ID:
P21917
Molecular Weight:
48359.86 Da
References
  1. Nasrallah HA: Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles. Mol Psychiatry. 2008 Jan;13(1):27-35. Epub 2007 Sep 11. [PubMed:17848919 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Histamine receptor activity
Specific Function:
In peripheral tissues, the H1 subclass of histamine receptors mediates the contraction of smooth muscles, increase in capillary permeability due to contraction of terminal venules, and catecholamine release from adrenal medulla, as well as mediating neurotransmission in the central nervous system.
Gene Name:
HRH1
Uniprot ID:
P35367
Molecular Weight:
55783.61 Da
References
  1. Richelson E, Souder T: Binding of antipsychotic drugs to human brain receptors focus on newer generation compounds. Life Sci. 2000 Nov 24;68(1):29-39. [PubMed:11132243 ]
  2. Nasrallah HA: Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles. Mol Psychiatry. 2008 Jan;13(1):27-35. Epub 2007 Sep 11. [PubMed:17848919 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Protein heterodimerization activity
Specific Function:
This alpha-adrenergic receptor mediates its action by association with G proteins that activate a phosphatidylinositol-calcium second messenger system. Its effect is mediated by G(q) and G(11) proteins. Nuclear ADRA1A-ADRA1B heterooligomers regulate phenylephrine(PE)-stimulated ERK signaling in cardiac myocytes.
Gene Name:
ADRA1A
Uniprot ID:
P35348
Molecular Weight:
51486.005 Da
References
  1. Richelson E, Souder T: Binding of antipsychotic drugs to human brain receptors focus on newer generation compounds. Life Sci. 2000 Nov 24;68(1):29-39. [PubMed:11132243 ]
  2. Nasrallah HA: Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles. Mol Psychiatry. 2008 Jan;13(1):27-35. Epub 2007 Sep 11. [PubMed:17848919 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Protein heterodimerization activity
Specific Function:
This alpha-adrenergic receptor mediates its action by association with G proteins that activate a phosphatidylinositol-calcium second messenger system. Its effect is mediated by G(q) and G(11) proteins. Nuclear ADRA1A-ADRA1B heterooligomers regulate phenylephrine (PE)-stimulated ERK signaling in cardiac myocytes.
Gene Name:
ADRA1B
Uniprot ID:
P35368
Molecular Weight:
56835.375 Da
References
  1. Richelson E, Souder T: Binding of antipsychotic drugs to human brain receptors focus on newer generation compounds. Life Sci. 2000 Nov 24;68(1):29-39. [PubMed:11132243 ]
  2. Nasrallah HA: Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles. Mol Psychiatry. 2008 Jan;13(1):27-35. Epub 2007 Sep 11. [PubMed:17848919 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Alpha1-adrenergic receptor activity
Specific Function:
This alpha-adrenergic receptor mediates its effect through the influx of extracellular calcium.
Gene Name:
ADRA1D
Uniprot ID:
P25100
Molecular Weight:
60462.205 Da
References
  1. Richelson E, Souder T: Binding of antipsychotic drugs to human brain receptors focus on newer generation compounds. Life Sci. 2000 Nov 24;68(1):29-39. [PubMed:11132243 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Thioesterase binding
Specific Function:
Alpha-2 adrenergic receptors mediate the catecholamine-induced inhibition of adenylate cyclase through the action of G proteins. The rank order of potency for agonists of this receptor is oxymetazoline > clonidine > epinephrine > norepinephrine > phenylephrine > dopamine > p-synephrine > p-tyramine > serotonin = p-octopamine. For antagonists, the rank order is yohimbine > phentolamine = mianser...
Gene Name:
ADRA2A
Uniprot ID:
P08913
Molecular Weight:
48956.275 Da
References
  1. Richelson E, Souder T: Binding of antipsychotic drugs to human brain receptors focus on newer generation compounds. Life Sci. 2000 Nov 24;68(1):29-39. [PubMed:11132243 ]
  2. Nasrallah HA: Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles. Mol Psychiatry. 2008 Jan;13(1):27-35. Epub 2007 Sep 11. [PubMed:17848919 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Epinephrine binding
Specific Function:
Alpha-2 adrenergic receptors mediate the catecholamine-induced inhibition of adenylate cyclase through the action of G proteins. The rank order of potency for agonists of this receptor is clonidine > norepinephrine > epinephrine = oxymetazoline > dopamine > p-tyramine = phenylephrine > serotonin > p-synephrine / p-octopamine. For antagonists, the rank order is yohimbine > chlorpromazine > phent...
Gene Name:
ADRA2B
Uniprot ID:
P18089
Molecular Weight:
49565.8 Da
References
  1. Richelson E, Souder T: Binding of antipsychotic drugs to human brain receptors focus on newer generation compounds. Life Sci. 2000 Nov 24;68(1):29-39. [PubMed:11132243 ]
  2. Nasrallah HA: Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles. Mol Psychiatry. 2008 Jan;13(1):27-35. Epub 2007 Sep 11. [PubMed:17848919 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Protein homodimerization activity
Specific Function:
Alpha-2 adrenergic receptors mediate the catecholamine-induced inhibition of adenylate cyclase through the action of G proteins.
Gene Name:
ADRA2C
Uniprot ID:
P18825
Molecular Weight:
49521.585 Da
References
  1. Richelson E, Souder T: Binding of antipsychotic drugs to human brain receptors focus on newer generation compounds. Life Sci. 2000 Nov 24;68(1):29-39. [PubMed:11132243 ]
  2. Nasrallah HA: Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles. Mol Psychiatry. 2008 Jan;13(1):27-35. Epub 2007 Sep 11. [PubMed:17848919 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Phosphatidylinositol phospholipase c activity
Specific Function:
The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the action of G proteins. Primary transducing effect is Pi turnover.
Gene Name:
CHRM1
Uniprot ID:
P11229
Molecular Weight:
51420.375 Da
References
  1. Richelson E, Souder T: Binding of antipsychotic drugs to human brain receptors focus on newer generation compounds. Life Sci. 2000 Nov 24;68(1):29-39. [PubMed:11132243 ]
  2. Nasrallah HA: Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles. Mol Psychiatry. 2008 Jan;13(1):27-35. Epub 2007 Sep 11. [PubMed:17848919 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
G-protein coupled acetylcholine receptor activity
Specific Function:
The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the action of G proteins. Primary transducing effect is adenylate cyclase inhibition. Signaling promotes phospholipase C activity, leading to the release of inositol trisphosphate (IP3); this then trigge...
Gene Name:
CHRM2
Uniprot ID:
P08172
Molecular Weight:
51714.605 Da
References
  1. Richelson E, Souder T: Binding of antipsychotic drugs to human brain receptors focus on newer generation compounds. Life Sci. 2000 Nov 24;68(1):29-39. [PubMed:11132243 ]
  2. Nasrallah HA: Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles. Mol Psychiatry. 2008 Jan;13(1):27-35. Epub 2007 Sep 11. [PubMed:17848919 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Receptor activity
Specific Function:
The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the action of G proteins. Primary transducing effect is Pi turnover.
Gene Name:
CHRM3
Uniprot ID:
P20309
Molecular Weight:
66127.445 Da
References
  1. Richelson E, Souder T: Binding of antipsychotic drugs to human brain receptors focus on newer generation compounds. Life Sci. 2000 Nov 24;68(1):29-39. [PubMed:11132243 ]
  2. Nasrallah HA: Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles. Mol Psychiatry. 2008 Jan;13(1):27-35. Epub 2007 Sep 11. [PubMed:17848919 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Guanyl-nucleotide exchange factor activity
Specific Function:
The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the action of G proteins. Primary transducing effect is inhibition of adenylate cyclase.
Gene Name:
CHRM4
Uniprot ID:
P08173
Molecular Weight:
53048.65 Da
References
  1. Richelson E, Souder T: Binding of antipsychotic drugs to human brain receptors focus on newer generation compounds. Life Sci. 2000 Nov 24;68(1):29-39. [PubMed:11132243 ]
  2. Nasrallah HA: Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles. Mol Psychiatry. 2008 Jan;13(1):27-35. Epub 2007 Sep 11. [PubMed:17848919 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Phosphatidylinositol phospholipase c activity
Specific Function:
The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the action of G proteins. Primary transducing effect is Pi turnover.
Gene Name:
CHRM5
Uniprot ID:
P08912
Molecular Weight:
60073.205 Da
References
  1. Richelson E, Souder T: Binding of antipsychotic drugs to human brain receptors focus on newer generation compounds. Life Sci. 2000 Nov 24;68(1):29-39. [PubMed:11132243 ]
  2. Nasrallah HA: Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles. Mol Psychiatry. 2008 Jan;13(1):27-35. Epub 2007 Sep 11. [PubMed:17848919 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Vitamin d3 25-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation reactions (e.g. caffeine 8-oxidation, omeprazole sulphoxidation, midazolam 1'-hydroxylation and midazolam 4-hydroxylation) of structurally unrelated compounds, including steroids, fatty acids, and xenobiot...
Gene Name:
CYP3A4
Uniprot ID:
P08684
Molecular Weight:
57342.67 Da
References
  1. Urichuk L, Prior TI, Dursun S, Baker G: Metabolism of atypical antipsychotics: involvement of cytochrome p450 enzymes and relevance for drug-drug interactions. Curr Drug Metab. 2008 Jun;9(5):410-8. [PubMed:18537577 ]
  2. DeVane CL, Nemeroff CB: Clinical pharmacokinetics of quetiapine: an atypical antipsychotic. Clin Pharmacokinet. 2001;40(7):509-22. [PubMed:11510628 ]
  3. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
  4. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Oxygen binding
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics.
Gene Name:
CYP3A5
Uniprot ID:
P20815
Molecular Weight:
57108.065 Da
References
  1. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Oxygen binding
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics.
Gene Name:
CYP3A7
Uniprot ID:
P24462
Molecular Weight:
57525.03 Da
References
  1. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Steroid hydroxylase activity
Specific Function:
Responsible for the metabolism of a number of therapeutic agents such as the anticonvulsant drug S-mephenytoin, omeprazole, proguanil, certain barbiturates, diazepam, propranolol, citalopram and imipramine.
Gene Name:
CYP2C19
Uniprot ID:
P33261
Molecular Weight:
55930.545 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic antidepressants.
Gene Name:
CYP2D6
Uniprot ID:
P10635
Molecular Weight:
55768.94 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Xenobiotic-transporting atpase activity
Specific Function:
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name:
ABCB1
Uniprot ID:
P08183
Molecular Weight:
141477.255 Da
References
  1. Boulton DW, DeVane CL, Liston HL, Markowitz JS: In vitro P-glycoprotein affinity for atypical and conventional antipsychotics. Life Sci. 2002 May 31;71(2):163-9. [PubMed:12031686 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on December 09, 2016 03:54